[{"text": "Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025 Calidi Biotherapeutics, Inc Mon, Jan 13, 2025, 4:00 PM 4 min read In This Article: CLDI +38.49% CLDWW +231.25% Calidi Biotherapeutics, Inc SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (\u201cCalidi\u201d), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its abstract, titled \"Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites\" , has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting April 25-30 , 2025 in Chicago, IL. This significant milestone reflects Calidi\u2019s ongoing commitment to advancing systemic enveloped virotherapy as a transformative approach to target and kill metastatic cancers, which are the leading cause of cancer-related mortality. The data presented will focus on the development of Calidi's proprietary RTNova systemic platform, showcasing its potential to overcome current barriers in metastatic cancer treatment by enabling targeted systemic delivery to multiple tumor sites without rapid elimination by the body\u2019s immune system. This systemic platform addresses the challenges of treating advanced-stage metastatic cancers, including lung cancer, when intratumoral administration is not feasible. Calidi designed a novel vaccinia virus strain that is enveloped with a human cell membrane (extracellular enveloped virus or EEV) that offers protection while targeting distant tumors and upon reaching the tumor, induces a robust response from the patient\u2019s immune cells which produces a more durable therapeutic effect. \u201cOur acceptance to present at AACR underscores the transformative potential of our systemic virotherapy platform,\u201d said Allan Camaisa, CEO and Chairman of Calidi Biotherapeutics. \u201cWe are proud to share our pioneering research on the RTNova systemic virotherapy platform, which has the potential to redefine how metastatic cancers are treated and significantly improve outcomes for patients facing advanced-stage disease.\u201d In addition to the AACR presentation, Calidi plans to submit an abstract to unveil further key data at the ASCO Annual Meeting in June 2025, highlighting its progress toward selecting a lead clinical candidate for RTNova. This work complements Calidi\u2019s ongoing clinical and preclinical efforts in localized and intratumoral cell-based virotherapies with SNV (SuperNova) and NNV (NeuroNova), collectively demonstrating Calidi's approach to revolutionizing cancer treatment. About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi\u2019s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi\u2019s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi\u2019s preclinical off-the-shelf enveloped virotherapies, are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com . Story Continues Forward-Looking Statements This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company\u2019s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024, and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time. Corporate Communications: Dave Gentry, CEO RedChip Companies, Inc. 1-407-644-4256 CLDI@redchip.com Source: Calidi Biotherapeutics, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLDI", "date": "2025-01-13T13:00:00+00:00", "sentiment": {"score": 0.5660044364631176, "confidence": 0.5751690864562988, "probabilities": {"positive": 0.5751690864562988, "negative": 0.009164649993181229, "neutral": 0.41566622257232666}}, "embedding": [-0.06469105184078217, -0.09083133190870285, -0.17969068884849548, -0.13287955522537231, 0.07276380062103271, -0.1622021198272705, -0.057882342487573624, 0.060701481997966766, 0.1961156129837036, 0.08674941956996918, -0.029992904514074326, -0.10216045379638672, 0.06739857792854309, 0.04942067712545395, 0.07434149086475372, -0.04033029079437256, -0.003650608006864786, 0.05353626608848572, -0.09544578939676285, 0.1720370054244995, 0.03401242569088936, 0.096000537276268, -0.012274482287466526, 0.003386181313544512, -0.11148129403591156, 0.041126348078250885, -0.20027309656143188, -0.021370645612478256, -0.2413550615310669, -0.01959434151649475, 0.023170894011855125, 0.02866729348897934, 0.005506834015250206, 0.08277641236782074, -0.06678719073534012, -0.022040775045752525, -0.2495388388633728, 0.1549104005098343, -0.2930498719215393, -0.13518232107162476, -0.11444302648305893, -0.09178832173347473, -0.09366503357887268, 0.09786968678236008, -0.07890716940164566, -0.1490817368030548, -0.21298089623451233, -0.02099008299410343, 0.10367454588413239, 0.2440166175365448, -0.18466511368751526, -0.028621049597859383, -0.11481622606515884, 0.26795026659965515, -0.058425821363925934, 0.1119508445262909, -0.1606108695268631, 0.02280014380812645, 0.013339992612600327, -0.05010244622826576, 0.056096166372299194, -0.10129466652870178, 0.04695950448513031, 0.02283044159412384, 0.07853677868843079, -0.07487432658672333, 0.025122422724962234, 0.049196209758520126, -0.05045545473694801, 0.06194616109132767, 0.003466770052909851, 0.016425644978880882, -0.016536947339773178, 0.22022168338298798, 0.07751931995153427, 0.1170530691742897, 0.1365438550710678, 0.11703243851661682, 0.23093195259571075, -0.021276473999023438, 0.19504159688949585, 0.10215838998556137, 0.03600934147834778, 0.11719179153442383, 0.02873365581035614, 0.10935218632221222, 0.0212892834097147, 0.08693289756774902, 0.03632569685578346, 0.03891972452402115, 0.1337665319442749, 0.10273699462413788, 0.14614245295524597, 0.039139021188020706, -0.034107014536857605, 0.013204917311668396, -0.006612788885831833, -0.0875384658575058, -0.028044773265719414, -0.0043993741273880005, -0.13283595442771912, -0.07297365367412567, -0.11292599141597748, -0.06631278991699219, 0.03600117936730385, -0.09064339101314545, -0.07622241228818893, 0.059830192476511, -0.1273951381444931, -0.021068047732114792, 0.12261806428432465, -0.008286934345960617, 0.054437123239040375, -0.0708160400390625, 0.1317678838968277, 0.2901548743247986, -0.09000582993030548, 0.03895537555217743, 0.1304815262556076, -0.08676320314407349, -0.09979706257581711, 0.016059432178735733, -0.07836660742759705, -0.10120716691017151, 0.08705928921699524, 0.1341537982225418, -0.09878678619861603, 9.742971785459263e-33, 0.06626614183187485, 0.07198908925056458, 0.057720404118299484, 0.1951093077659607, 0.04216265305876732, -0.12657400965690613, 0.07377853244543076, -0.03851165622472763, -0.14848674833774567, -0.09339596331119537, 0.00387568143196404, 0.038569629192352295, -0.024332907050848007, 0.21643026173114777, -0.021788274869322777, -0.09931138157844543, -0.04603138566017151, 0.049616869539022446, -0.02902292087674141, -0.12338025867938995, 0.12256333976984024, 0.07530806958675385, 0.05350865051150322, -0.08042874932289124, -0.16772982478141785, 0.11289243400096893, -0.13826756179332733, 0.10271430015563965, 0.04524282366037369, 0.07268165796995163, -0.1992456316947937, 0.1160096526145935, 0.02736750803887844, -0.00809918437153101, -0.006043579429388046, -0.043829064816236496, -0.033725179731845856, -0.1932489275932312, -0.088176429271698, 0.19826766848564148, 0.01440444216132164, 0.10360971093177795, -0.12078332901000977, -0.038206301629543304, 0.10300659388303757, -0.09942904114723206, -0.03954261541366577, 0.13512206077575684, -0.026574112474918365, 0.1312674582004547, 0.017214423045516014, -0.05355187505483627, 0.055269211530685425, -0.05203479528427124, -0.1558428406715393, 0.10618534684181213, -0.15686289966106415, -0.016819609329104424, 0.001282679382711649, -0.02438059262931347, -0.017700564116239548, -0.008790623396635056, -0.006289106328040361, 0.14698058366775513, -0.0834147036075592, 0.028436832129955292, 0.03260723128914833, -0.1223471462726593, -0.0429721362888813, 0.16797181963920593, -0.12069372087717056, 0.06708061695098877, 0.20655766129493713, -0.015977591276168823, 0.16055411100387573, -0.0020218947902321815, 0.07693946361541748, 0.06501603871583939, -0.05432704836130142, 0.1677093505859375, -0.09849929809570312, 0.10695695877075195, -0.13311150670051575, 0.0998755395412445, -0.04979516193270683, -0.18081296980381012, -0.011084839701652527, 0.0007719649001955986, -0.12211772799491882, -0.06432683765888214, 0.08141814172267914, -0.05699159950017929, -0.04043325409293175, 0.09192220866680145, -0.11194761842489243, -9.555722147528996e-33, 0.07705902308225632, -0.098835289478302, 0.0561661571264267, 0.033498287200927734, 0.03166918084025383, 0.2013503462076187, 0.03554742410778999, -0.21924063563346863, 0.018306605517864227, -0.19167250394821167, 0.04953660070896149, 0.04647305607795715, 0.04785293713212013, -0.08481510728597641, -0.06706545501947403, 0.003793954849243164, 0.044760286808013916, -0.17579492926597595, -0.22800755500793457, -0.002804781310260296, -0.030856657773256302, 0.18235714733600616, -0.04175063222646713, 0.08170626312494278, 0.0737379938364029, -0.1256936639547348, 0.1932501494884491, 0.060566965490579605, 0.060050807893276215, -0.05638262629508972, 0.027867957949638367, 0.038029029965400696, -0.1840590536594391, -0.021673085168004036, -0.0398482084274292, 0.12138643115758896, 0.19830036163330078, -0.18002748489379883, 0.06358984112739563, -0.10727645456790924, 0.014857526868581772, -0.12032568454742432, -0.27395448088645935, -0.03965327888727188, 0.031247645616531372, 0.05791308730840683, 0.09552820771932602, 0.12011785805225372, 0.1361391544342041, 0.10654148459434509, -0.006678451783955097, -0.0705060362815857, -0.09953483939170837, 0.0408320352435112, -0.03182469308376312, 0.10021214187145233, 0.00851353071630001, 0.03452764078974724, 0.013400973752140999, 0.05889083445072174, -0.006579629611223936, 0.04256967827677727, 0.0017590448260307312, -0.12159121036529541, 0.07315413653850555, 0.17501533031463623, 0.12926682829856873, -0.03012806549668312, -0.031052442267537117, -0.1484321653842926, 0.0256566870957613, -0.09147899597883224, -0.01815865747630596, -0.09590800851583481, 0.06400657445192337, -0.020273663103580475, 0.041756629943847656, -0.1767287254333496, -0.16958144307136536, 0.07423484325408936, -0.015129863284528255, 0.025269322097301483, 0.05920564383268356, -0.03348946198821068, 0.19178324937820435, 0.17650988698005676, -0.011270565912127495, 0.04913632199168205, -0.06059174984693527, 0.12997430562973022, -0.07529707998037338, -0.17144212126731873, -0.08502879738807678, 0.18550118803977966, 0.03524242714047432, -1.0023916985346659e-07, 0.19842109084129333, 0.0925690233707428, -0.09329037368297577, -0.13724958896636963, -0.05530732870101929, 0.06696520000696182, 0.029947426170110703, 0.03786204382777214, -0.04043698310852051, 0.13211268186569214, 0.054076649248600006, 0.1235840767621994, -0.06880944967269897, 0.09980271011590958, 0.06739180535078049, 0.12980684638023376, -0.04620746523141861, -0.005843758583068848, -0.165599524974823, -0.12264342606067657, -0.07433705031871796, -0.04146265983581543, -0.007795731537044048, -0.16011255979537964, 0.06952399760484695, -0.06707992404699326, -0.05980248004198074, -0.058869123458862305, 0.034515880048274994, -0.1428156942129135, -0.10801231861114502, -0.08412762731313705, -0.06582464277744293, -0.024308957159519196, -0.09847145527601242, 0.030603831633925438, 0.044513799250125885, -0.09703534841537476, 0.029279224574565887, 0.21533557772636414, 0.12691079080104828, 0.05133260786533356, -0.11174540221691132, -0.030768681317567825, -0.07517056167125702, 0.0851089358329773, -0.14569193124771118, 0.026161614805459976, -0.08211623132228851, 0.01439560204744339, -0.02027139440178871, -0.04888651520013809, -0.026504959911108017, 0.026594433933496475, -0.07071450352668762, 0.24370785057544708, -0.060610659420490265, -0.14912149310112, 0.13076505064964294, 0.04141819849610329, 0.016654156148433685, -0.04115213826298714, 0.13739526271820068, -0.05771208554506302], "changes": {"1wk": -2.720352008546748}}, {"text": "PREMIUM Calidi Biotherapeutics Prices $4.25 Million Stock Offering; Shares Fall Pre-Bell MT Newswires Fri, Jan 10, 2025, 5:26 PM Calidi Biotherapeutics' (CLDI) shares fell by more than 30% in premarket trading on Friday after the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLDI", "date": "2025-01-10T14:26:27+00:00", "sentiment": {"score": -0.8968241205438972, "confidence": 0.9073631763458252, "probabilities": {"positive": 0.010539055801928043, "negative": 0.9073631763458252, "neutral": 0.08209774643182755}}, "embedding": [0.02580823004245758, -0.10558445006608963, -0.06965811550617218, 0.09347500652074814, 0.07897575199604034, -0.0601143054664135, -0.03098260425031185, 0.05466474965214729, 0.2260533571243286, 0.08140017837285995, 0.20148715376853943, -0.11128601431846619, -0.03354610502719879, 0.14286834001541138, 0.03266575559973717, -0.12693651020526886, -0.028799833729863167, -0.06848861277103424, -0.05697372183203697, 0.14572732150554657, -0.20959633588790894, -0.0016737997066229582, 0.017988547682762146, 0.1586967408657074, 0.03269156068563461, 0.024874670431017876, -0.17089317739009857, -0.060714032500982285, -0.08506501466035843, 0.04347123205661774, -0.10102846473455429, 0.05456775426864624, 0.19322480261325836, 0.04159345477819443, 0.05620277300477028, -0.007183511275798082, -0.11487292498350143, 0.04529119282960892, -0.14041244983673096, 0.037760235369205475, -0.02849590592086315, -0.1271410435438156, -0.11614861339330673, 0.10991083085536957, -0.15786081552505493, -0.12905317544937134, -0.025844959542155266, 0.07458461076021194, 0.1351625621318817, 0.09878621995449066, -0.16638556122779846, 0.039764728397130966, -0.017334114760160446, -0.060036830604076385, -0.059420354664325714, 0.0018200643826276064, -0.18223229050636292, -0.10266239196062088, 0.02163592539727688, 0.03344682604074478, 0.10306429862976074, -0.07482103258371353, -0.06928505003452301, 0.039841536432504654, 0.0413505956530571, 0.03888087719678879, 0.03666113317012787, 0.09438682347536087, 0.05776955187320709, -0.09013821184635162, 0.09151283651590347, 0.06435563415288925, 0.04702480137348175, 0.018567649647593498, 0.011588158085942268, 0.19281676411628723, 0.13987569510936737, -0.008679313585162163, 0.15993015468120575, -0.12092450261116028, -0.07484156638383865, -0.09681714326143265, -0.11874448508024216, 0.029029276221990585, 0.099882110953331, 0.0995902568101883, 0.30951187014579773, 0.05371074751019478, 0.014057056047022343, -0.16901777684688568, 0.22077077627182007, 0.057966604828834534, 0.04403294622898102, -0.011488254182040691, -0.25162312388420105, 0.11772561073303223, -0.11436014622449875, -0.10108781605958939, -0.1044526919722557, -0.10133808106184006, -0.0012233059387654066, 0.03389212116599083, -0.16325892508029938, 0.01772807352244854, -0.03927706927061081, -0.17814208567142487, -0.00043577663018368185, 0.1333133578300476, -0.06802267581224442, 0.06664140522480011, 0.09435492008924484, 0.07450515776872635, -0.038688670843839645, 0.012266026809811592, -0.06907077133655548, 0.28234684467315674, -0.08406461775302887, -0.046805236488580704, 0.07608983665704727, 0.023594960570335388, -0.16190804541110992, 0.05316302552819252, -0.14471936225891113, -0.08571959286928177, 0.021165451034903526, -0.0036500340793281794, -0.06830284744501114, 1.3768305253056334e-32, 0.08850155770778656, 0.08553551882505417, -0.015148191712796688, -0.0849386677145958, -0.07034414261579514, 0.005710460711270571, 0.03359631076455116, -0.1597568243741989, -0.08783846348524094, -0.10355748981237411, -0.08296513557434082, 0.15224191546440125, -0.1117008700966835, 0.06040233373641968, -0.020123394206166267, -0.19245661795139313, 0.0026283145416527987, -0.03195011243224144, 0.23996120691299438, -0.0180891714990139, 0.032307907938957214, 0.17967694997787476, -0.05793553590774536, -0.030754651874303818, -0.09457875788211823, 0.14032910764217377, -0.09659568220376968, -0.05354594811797142, 0.13340425491333008, 0.16302384436130524, -0.010583101771771908, 0.022046128287911415, -0.05478743836283684, -0.04769996926188469, 0.008603551425039768, 0.15459826588630676, -0.013842427171766758, -0.024434681981801987, -0.041177209466695786, 0.13599635660648346, -0.05871162936091423, 0.12211306393146515, -0.0018051806837320328, -0.144235759973526, -0.01316516287624836, -0.08350490778684616, -0.07761823385953903, 0.11442134529352188, 0.10294414311647415, 0.015796668827533722, -0.15196508169174194, 0.13941241800785065, -0.07067175954580307, 0.04553151875734329, -0.1526513248682022, 0.018580825999379158, -0.03244556114077568, -0.2801007032394409, -0.036618784070014954, 0.010987448506057262, 0.1446477323770523, 0.2056473344564438, 0.018921149894595146, -0.03718848153948784, -0.266469269990921, -0.006355281453579664, -0.1412847340106964, -0.08753059059381485, -0.13457471132278442, 0.2176968902349472, -0.03818502277135849, 0.01634363830089569, 0.0894409641623497, -0.047515638172626495, 0.09780609607696533, -0.009856251999735832, -0.09848403185606003, -0.03983960300683975, 0.1683143675327301, 0.11979135125875473, 0.16364309191703796, 0.053518809378147125, 0.10747341811656952, 0.05330798029899597, 0.018367242068052292, -0.002953475108370185, -0.06992282718420029, 0.12871390581130981, -0.11318545043468475, -0.061157166957855225, 0.06323952227830887, -0.08359961211681366, -0.029693031683564186, 0.03841403126716614, -0.06101560965180397, -1.5195252539198894e-32, 0.035166431218385696, -0.08484168350696564, 0.190818190574646, 0.029373321682214737, -0.08408435434103012, 0.005148787051439285, -0.010250884108245373, 0.07011115550994873, -0.0018538148142397404, 0.06460003554821014, 0.03844713419675827, 0.12130940705537796, -0.0639929249882698, 0.007268182002007961, 0.01093766838312149, 0.16702385246753693, 0.06084013730287552, -0.20044779777526855, 0.052702877670526505, -0.13003522157669067, -0.19040530920028687, 0.19465355575084686, -0.02319481037557125, 0.18818266689777374, 0.15273000299930573, -0.0754009261727333, 0.15179620683193207, 0.04097844287753105, 0.17039327323436737, -0.08921114355325699, -0.1263795644044876, -0.03224213793873787, -0.23779982328414917, 0.060006964951753616, -0.04029795154929161, -0.0436403825879097, 0.06525467336177826, 0.07633150368928909, 0.020141057670116425, -0.04035598412156105, 0.038581423461437225, -0.17231117188930511, -0.05402548983693123, 0.100812166929245, 0.17998342216014862, -0.16203059256076813, -0.012870535254478455, -0.007971495389938354, 0.20037493109703064, 0.24822497367858887, 0.03398013487458229, -0.006250398233532906, 0.02464861050248146, 0.08954467624425888, -0.0893772765994072, 0.05731683224439621, 0.020278513431549072, 0.15293993055820465, -0.23735590279102325, -0.057734183967113495, -0.07011083513498306, 0.0704297199845314, -0.10369446873664856, -0.020330188795924187, 0.048668865114450455, 0.13381873071193695, -0.026334280148148537, 0.011032020673155785, 0.06930667161941528, -0.24939613044261932, 0.17555968463420868, -0.16370618343353271, -0.007818560115993023, -0.35402414202690125, 0.0702177882194519, 0.16291400790214539, -0.23434050381183624, -0.004530536476522684, 0.05711597949266434, 0.33769333362579346, 0.03843289613723755, 0.09379812330007553, 0.08199847489595413, 0.007013607770204544, -0.05277896672487259, 0.026181738823652267, 0.04359506443142891, -0.04687280207872391, -0.11745966225862503, 0.0638638436794281, -0.15367090702056885, -0.15380340814590454, 0.09742164611816406, 0.07732684910297394, 0.030465444549918175, -9.973780379368691e-08, 0.07525104284286499, -0.09910951554775238, 0.04686329513788223, 0.0791797935962677, 0.09387418627738953, -0.04360298439860344, -0.011955750174820423, 0.077110156416893, 0.054602399468421936, 0.2627732753753662, 0.032858267426490784, 0.09408717602491379, -0.19304005801677704, 0.15737266838550568, -0.1333867311477661, 0.0223096776753664, -0.051734402775764465, -0.03080260194838047, -0.0007189444731920958, -0.19891011714935303, -0.06772101670503616, -0.00042393026524223387, 0.1476002186536789, 0.0014527983730658889, -0.106388621032238, 0.03302786126732826, -0.07241234928369522, -0.15083296597003937, -0.0411280021071434, -0.006643611937761307, 0.012131339870393276, -0.17816409468650818, -0.08697201311588287, -0.04724087938666344, 0.019994521513581276, 0.03787756338715553, -0.05146133154630661, -0.0268145389854908, -0.04839257523417473, 0.233441561460495, 0.026854975149035454, -0.12055551260709763, -0.04358947277069092, 0.04025862738490105, 0.16086620092391968, 0.042292091995477676, -0.24926981329917908, -0.022514253854751587, 0.020824212580919266, -0.16397356986999512, 0.1256302446126938, -0.0157803725451231, -0.10085712373256683, 0.044603198766708374, -0.11622645705938339, 0.1305007040500641, -0.04798620939254761, -0.13706006109714508, -0.13074851036071777, 0.07258955389261246, -0.05940471962094307, -0.30099761486053467, 0.026254961267113686, 0.05367322266101837], "changes": {"1wk": -2.076502006070814}}, {"text": "Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock Calidi Biotherapeutics, Inc Sat, Jan 11, 2025, 12:30 AM 4 min read In This Article: CLDI +38.49% CLDWW +231.25% Calidi Biotherapeutics, Inc SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (\u201cCalidi\u201d), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 5,000,000 shares of common stock at $0.85 per share for gross proceeds of approximately $4.25 million. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this offering. The securities described above public offering were offered pursuant to registration statements on Form S-3 (File No. 333-282456), which were declared effective by the United States Securities and Exchange Commission (\"SEC\") on October 10, 2024. The offering was made solely by means of a prospectus. A final prospectus relating to the offering was filed with the SEC on January 10, 2025, and is available on the SEC's website located at http://www.sec.gov . Copies of the final prospectus can be obtained at the SEC's website at http://www.sec.gov or from Ladenburg Thalmann & Co. Inc. Electronic copies of the final prospectus relating to the offering may be obtained, when available, from Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, New York 10019, or by telephone at (212) 409-2000, or by email at prospectus@ladenburg.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi\u2019s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi\u2019s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi\u2019s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com . Story Continues Forward-Looking Statements This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company\u2019s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024 and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time. For Investors: Dave Gentry, CEO RedChip Companies, Inc. 1-407-644-4256 CLDI@redchip.com Source: Calidi Biotherapeutics, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLDI", "date": "2025-01-10T21:30:00+00:00", "sentiment": {"score": -0.0030537135899066925, "confidence": 0.023683546110987663, "probabilities": {"positive": 0.02062983252108097, "negative": 0.023683546110987663, "neutral": 0.955686628818512}}, "embedding": [-0.056975387036800385, -0.15330570936203003, -0.17259296774864197, -0.08773462474346161, -0.09124457836151123, -0.0286698080599308, 0.04384608194231987, 0.145692840218544, 0.23851659893989563, 0.04835045337677002, 0.09851790964603424, -0.04124286025762558, 0.005218541249632835, 0.04794686287641525, -0.03325756639242172, -0.07854846119880676, 0.04806587100028992, 0.012887375429272652, -0.08373299241065979, 0.25945180654525757, 0.041333094239234924, 0.004894030746072531, 0.03986366093158722, 0.05385737866163254, -0.030138233676552773, -0.026179729029536247, -0.07590776681900024, -0.053384214639663696, -0.23862288892269135, 0.0064315879717469215, 0.033974334597587585, 0.006107453256845474, 0.14113852381706238, -0.04252661019563675, 0.14512619376182556, 0.083048015832901, -0.13144221901893616, 0.06200209632515907, -0.016165653243660927, 0.06773269921541214, -0.09258821606636047, -0.0697038322687149, -0.07723286002874374, 0.11302497237920761, -0.07677153497934341, -0.07871006429195404, -0.17887473106384277, 0.13630907237529755, 0.05600529909133911, 0.19255077838897705, -0.1087295338511467, -0.00282671139575541, -0.05586932972073555, 0.10895279049873352, -0.044560085982084274, -0.05475866049528122, -0.127481609582901, -0.023587435483932495, -0.011080270633101463, 0.05973377078771591, 0.08363865315914154, -0.039026737213134766, -0.0050055584870278835, 0.0529855415225029, 0.1172032505273819, -0.03742744028568268, -0.011675785295665264, -0.06746579706668854, 0.006923643872141838, -0.16441728174686432, 0.1888498067855835, -0.06367802619934082, -0.008686846122145653, 0.12896965444087982, -0.10554675757884979, 0.13378970324993134, 0.16425752639770508, 0.13978073000907898, 0.09164927899837494, -0.07409396767616272, 0.05757209658622742, 0.06728789955377579, -0.022328784689307213, -0.010011041536927223, -0.02400629036128521, 0.09068960696458817, 0.13904140889644623, 0.15713277459144592, 0.12633076310157776, -0.061124272644519806, 0.11440775543451309, 0.03367731720209122, -0.011554833501577377, -0.0679008811712265, -0.09322086721658707, -0.034163251519203186, -0.040284618735313416, 0.02815469726920128, -0.0652739554643631, -0.0039360662922263145, -0.013314465060830116, -0.07639584690332413, -0.17004461586475372, -0.1058284118771553, -0.09418688714504242, -0.05395757034420967, -0.06312359124422073, 0.04987055063247681, -0.052414678037166595, 0.038196735084056854, -0.10391250252723694, 0.11011513322591782, -0.06845707446336746, 0.020820898935198784, -0.03587665781378746, 0.23197588324546814, -0.04401902109384537, 0.03192691504955292, 0.23312045633792877, -0.15348589420318604, 0.009661104530096054, 0.03695819154381752, -0.11304647475481033, -0.18219158053398132, -0.014389009214937687, -0.026313837617635727, -0.07982049882411957, 9.603721255292917e-33, -0.03992414474487305, 0.02391556277871132, 0.007499702274799347, 0.005274593830108643, -0.07819756865501404, -0.02337752655148506, 0.1181935966014862, -0.026823561638593674, -0.16937018930912018, -0.0015143658965826035, -0.12093745917081833, 0.14526259899139404, 0.005841058678925037, 0.050535060465335846, -0.015502812340855598, -0.05629759281873703, 0.05321516469120979, -0.004115755669772625, 0.17836710810661316, -0.08273006230592728, 0.08298128843307495, 0.18397316336631775, 0.0030886363238096237, 0.07425153255462646, -0.0961020216345787, 0.08648312091827393, -0.19454729557037354, -0.01716119982302189, 0.05467269942164421, 0.06999173760414124, -0.021625401452183723, 0.0064888144843280315, 0.08981390297412872, 0.013812421821057796, 0.07478637248277664, 0.05657844990491867, -0.06418456882238388, -0.136362686753273, 0.02379528433084488, 0.1419675499200821, -0.036800239235162735, 0.15863510966300964, -0.014967506751418114, -0.0826372504234314, 0.06520190834999084, -0.04388132318854332, -0.08725549280643463, 0.16453643143177032, 0.07753631472587585, 0.038167744874954224, -0.08933209627866745, 0.10032378137111664, -0.02595820277929306, -0.04798881337046623, -0.07961777597665787, -0.012296084314584732, -0.0843685194849968, -0.08353488147258759, -0.08648069947957993, 0.08766605705022812, 0.04374675452709198, 0.19798317551612854, -0.04323917254805565, -0.038745127618312836, -0.23833391070365906, -0.07025821506977081, -0.06173517554998398, -0.09987056255340576, 0.002131798304617405, 0.1405230164527893, -0.10661554336547852, 0.051660872995853424, 0.18567074835300446, 0.02150656096637249, 0.12928511202335358, -0.13521724939346313, 0.039301902055740356, 0.10131282359361649, 0.06622251868247986, 0.001855192705988884, 0.0934792309999466, 0.07073599100112915, 0.010227161459624767, 0.16094659268856049, 0.01935282163321972, 0.01347305066883564, -0.00495748408138752, 0.10505066066980362, -0.12111440300941467, -0.01591987907886505, -0.00976895447820425, -0.07154055684804916, -0.11150090396404266, 0.08915118128061295, -0.025762077420949936, -9.977443970197939e-33, -0.008878886699676514, -0.1946641206741333, 0.07994552701711655, -0.04493928328156471, -0.12899108231067657, 0.056654348969459534, 0.04427684098482132, -0.13797616958618164, -0.04663898050785065, -0.07950259000062943, 0.03903705254197121, 0.06803196668624878, 0.08416080474853516, -0.031179726123809814, -0.05325795337557793, 0.1370033472776413, -0.02914443053305149, -0.10063138604164124, -0.03946487978100777, -0.05441102758049965, 0.027969058603048325, 0.17586572468280792, -0.017789682373404503, -0.0024871230125427246, 0.09298659861087799, -0.08289897441864014, 0.10457470268011093, 0.10237699747085571, 0.12195445597171783, -0.02044614963233471, -0.07637228071689606, -0.07842233777046204, -0.2983390688896179, 0.13553282618522644, -0.06938436627388, -0.06318265944719315, 0.0906405821442604, -0.06701049208641052, 0.04797584190964699, -0.020458657294511795, 0.0033374717459082603, -0.09035897254943848, -0.011205000802874565, 0.07612499594688416, 0.0955030620098114, -0.1140531599521637, 0.05631687492132187, 0.042192406952381134, 0.13454340398311615, 0.1021471917629242, -0.07969056814908981, -0.005774963181465864, 0.012097412720322609, 0.044696975499391556, -0.09718045592308044, 0.04254602640867233, -0.01722623035311699, 0.027982257306575775, -0.062428683042526245, -0.050364766269922256, 0.09191134572029114, 0.16894064843654633, -0.003048935905098915, 0.02238064631819725, 0.1907440423965454, 0.11104436218738556, -0.04310368373990059, -0.007187445182353258, -0.06373350322246552, -0.1884804666042328, 0.05679848790168762, -0.22153502702713013, -0.003970941063016653, -0.2823706269264221, 0.0010257433168590069, 0.07885456830263138, -0.11207018792629242, -0.10453741252422333, -0.10788571089506149, 0.19230790436267853, 0.05020937696099281, 0.1017216295003891, 0.037769634276628494, 0.06463319063186646, 0.13045629858970642, 0.14084650576114655, 0.019971059635281563, -0.058783214539289474, -0.04742122441530228, 0.03741832077503204, -0.10265633463859558, -0.11513696610927582, 0.06491338461637497, 0.03371619060635567, -0.0423806831240654, -9.944670864570071e-08, 0.07907983660697937, 0.006229013204574585, 0.024872329086065292, -0.09591235220432281, 0.12072551250457764, -0.0051434226334095, -0.03614126890897751, -0.024035271257162094, 0.00767042301595211, 0.18918295204639435, 0.0890030637383461, 0.18744730949401855, -0.2213839441537857, 0.0805661529302597, -0.15892663598060608, -0.006404067389667034, -0.07641731202602386, 0.0008948296308517456, -0.046122368425130844, -0.06255625933408737, -0.10469551384449005, 0.009926017373800278, 0.042165178805589676, -0.042019471526145935, -0.03620211035013199, -0.004873753525316715, -0.015347275882959366, -0.09343142807483673, -0.029003538191318512, 0.05467212572693825, 0.05428919196128845, -0.15132823586463928, 0.06381554156541824, -0.03442670777440071, 0.004681050777435303, 0.002846440300345421, -0.07995396852493286, 0.09715968370437622, 0.04841608554124832, 0.21227025985717773, 0.041016966104507446, -0.05628682300448418, -0.021800469607114792, 0.10823177546262741, 0.17673492431640625, 0.03287696838378906, -0.2402002215385437, -0.08490146696567535, 0.09214432537555695, -0.11819204688072205, 0.014493774622678757, -0.12177541851997375, -0.10482095927000046, -0.035708002746105194, -0.12487943470478058, 0.12184727191925049, -0.06523354351520538, -0.09327620267868042, -0.008843531832098961, 0.07305965572595596, -0.03870795667171478, -0.2160722315311432, 0.1499926745891571, 0.0644935667514801], "changes": {"1wk": -2.295084935965396}}, {"text": "Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock Calidi Biotherapeutics, Inc Fri, Jan 10, 2025, 4:30 PM 4 min read In This Article: CLDI +38.49% CLDWW +231.25% Calidi Biotherapeutics, Inc SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies,\u00a0today announced that it priced its public offering of 5,000,000 shares of common stock at a price of $0.85 per share. The closing of the offering is expected to occur on or about January 10, 2025, subject to satisfaction of customary closing conditions. Ladenburg\u00a0Thalmann\u00a0& Co. Inc. is acting as exclusive placement agent for the offering. The gross proceeds to Calidi from the offering, before deducting the placement agent fees and other offering expenses payable by the Company, are expected to be approximately $4.25 million. Calidi intends to use the net proceeds from the offering for working capital and for general corporate purposes. The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which was declared effective by the United States Securities and Exchange Commission (\u201cSEC\u201d) on October 10, 2024. The offering will be made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov . Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting\u00a0Ladenburg\u00a0Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com , once available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi\u2019s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi\u2019s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi\u2019s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com . Story Continues Forward-Looking Statements This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company\u2019s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024, and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time. For Investors: Dave Gentry, CEO RedChip Companies, Inc. 1-407-644-4256 CLDI@redchip.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLDI", "date": "2025-01-10T13:30:00+00:00", "sentiment": {"score": -0.005720136687159538, "confidence": 0.02586895041167736, "probabilities": {"positive": 0.020148813724517822, "negative": 0.02586895041167736, "neutral": 0.9539822340011597}}, "embedding": [-0.05105289816856384, -0.08252638578414917, -0.13358816504478455, -0.007574777118861675, -0.05981531739234924, -0.014317336492240429, 0.06621897220611572, 0.12866976857185364, 0.24120120704174042, 0.0844617560505867, 0.11889754235744476, -0.10766752064228058, 0.03529012203216553, 0.07454369217157364, 7.503852248191833e-05, -0.11448489129543304, 0.01325383223593235, 0.03350488469004631, -0.12909196317195892, 0.19671131670475006, 0.04083971679210663, -0.013213280588388443, 0.01207019854336977, 0.042878370732069016, -0.02445891685783863, -0.08883151412010193, -0.052282050251960754, -0.029140282422304153, -0.18884386122226715, -0.024983160197734833, 0.04626660794019699, 0.04608378931879997, 0.09519873559474945, -0.022033173590898514, 0.14623436331748962, 0.05934363231062889, -0.14100801944732666, 0.02650492452085018, -0.011938156560063362, 0.0724431574344635, -0.06937284767627716, -0.06775821000337601, -0.09239646792411804, 0.09828807413578033, -0.06513837724924088, -0.08180733025074005, -0.07952242344617844, 0.16557569801807404, 0.05094025284051895, 0.08589531481266022, -0.12986314296722412, 0.0047763497568666935, -0.04194517061114311, 0.09407004714012146, -0.05381777882575989, -0.06776157021522522, -0.13412907719612122, -0.047929875552654266, 0.01359395869076252, 0.036384452134370804, 0.0321357361972332, -0.02681734599173069, -0.015147440135478973, -0.007738368585705757, 0.14814049005508423, -0.011538263410329819, 0.0005407053977251053, -0.04828217253088951, 0.022741710767149925, -0.05314357951283455, 0.1881696581840515, -0.05309537798166275, -0.020175399258732796, 0.09003036469221115, -0.10425400733947754, 0.1179339736700058, 0.13252264261245728, 0.1202971339225769, 0.10470782220363617, -0.07307586818933487, 0.04999430477619171, -0.010975277982652187, -0.051194146275520325, -0.09022291004657745, -0.00495062954723835, 0.04180816188454628, 0.1190066784620285, 0.11368076503276825, 0.14659807085990906, 0.0021638846956193447, 0.12210144102573395, -0.02914077416062355, -0.00040839938446879387, -0.08435970544815063, -0.01647667959332466, 0.01330481842160225, -0.05403454601764679, -0.0077199991792440414, -0.021498389542102814, 0.012543639168143272, 0.04120872542262077, -0.06331164389848709, -0.13476306200027466, -0.06893637031316757, -0.07139059156179428, -0.06519690155982971, -0.048536188900470734, 0.033911991864442825, -0.041307415813207626, 0.013880439102649689, -0.13688981533050537, 0.04845596104860306, -0.10707182437181473, 0.027066683396697044, -0.038146041333675385, 0.23391583561897278, 0.0613192543387413, 0.007429345510900021, 0.18148648738861084, -0.14174190163612366, 0.015311782248318195, 0.037469930946826935, -0.05463705584406853, -0.14802566170692444, -0.02956225723028183, -0.05978786572813988, -0.10074007511138916, 1.1875088581768513e-32, -0.02962435409426689, 0.047181136906147, -0.03243536502122879, -0.025466419756412506, -0.10254255682229996, -0.009338576346635818, 0.06843845546245575, -0.004692020360380411, -0.11949507892131805, 0.009926159866154194, -0.1231493130326271, 0.15297555923461914, 0.01637461967766285, 0.03577020764350891, 0.019211342558264732, -0.06116350740194321, 0.037281863391399384, 0.02645675279200077, 0.2235444188117981, -0.040702518075704575, 0.0875772088766098, 0.11834028363227844, -0.02865878865122795, 0.03697434812784195, -0.13677000999450684, 0.098337322473526, -0.15472963452339172, -0.056505896151065826, 0.015174102038145065, 0.05435996502637863, 0.000705324113368988, 0.019345607608556747, 0.04534149169921875, -0.01368688978254795, 0.04224419593811035, 0.031346943229436874, -0.04005999490618706, -0.08236054331064224, 0.0459044873714447, 0.15950046479701996, -0.03634997829794884, 0.14287346601486206, 0.0793815553188324, -0.06221117079257965, 0.005608409643173218, 0.017917660996317863, -0.08276236802339554, 0.1321525275707245, 0.07194939255714417, 0.04268469288945198, -0.0671771913766861, 0.09195645153522491, -0.006330681964755058, -0.06188755854964256, -0.07824839651584625, -0.0365685410797596, -0.0918358862400055, -0.08563195914030075, -0.05645386874675751, 0.07669645547866821, 0.017932573333382607, 0.14182771742343903, -0.06538335233926773, 0.008937928825616837, -0.2291821837425232, -0.016536055132746696, -0.07786360383033752, -0.027064431458711624, -0.01049189642071724, 0.09834053367376328, -0.06033659726381302, 0.027438513934612274, 0.16352766752243042, -0.037524670362472534, 0.10312157869338989, -0.12466783821582794, 0.04753229767084122, 0.0815044641494751, 0.07201041281223297, 0.007010996341705322, 0.06133534759283066, 0.0612277053296566, 0.01046251691877842, 0.1281319409608841, -0.010766714811325073, 0.04549305886030197, -0.051972895860672, 0.0649641677737236, -0.06619296967983246, 0.0040038032457232475, 0.05850846692919731, -0.056455329060554504, -0.10984957963228226, 0.05637872591614723, 0.02673032507300377, -1.1049311881839518e-32, -0.04737725481390953, -0.10761375725269318, -0.0027228519320487976, -0.02808615192770958, -0.07975807785987854, 0.036362338811159134, 0.06605243682861328, -0.09792597591876984, -0.017532844096422195, -0.06571520119905472, -0.04792255163192749, 0.02431122399866581, 0.05275612324476242, -0.030934792011976242, -0.09571775048971176, 0.07224688678979874, -0.025732269510626793, -0.07320041954517365, 0.0027385298162698746, -0.05447351559996605, -0.041170019656419754, 0.20590740442276, -0.006831703707575798, 0.011387165635824203, 0.11015600711107254, -0.02117466926574707, 0.08598946779966354, 0.11455772817134857, 0.09209385514259338, 0.004802520852535963, -0.038534823805093765, -0.06622066348791122, -0.2508366107940674, 0.04700492322444916, -0.08029258251190186, -0.05423273146152496, 0.13287022709846497, 0.005859185941517353, 0.010731592774391174, 0.0006363913416862488, 0.040021564811468124, -0.07292035222053528, 0.02198980748653412, 0.07654977589845657, 0.12538306415081024, -0.13790985941886902, 0.0706910490989685, -0.01750313490629196, 0.16814178228378296, 0.1435394287109375, -0.05063365399837494, -0.008612429723143578, -0.0015901392325758934, 0.04971868917346001, -0.1344706267118454, 0.06943698227405548, 0.001957416534423828, 0.04632559418678284, -0.06426027417182922, -0.014186304062604904, 0.09769488871097565, 0.16007739305496216, -0.012696958146989346, -0.0042349910363554955, 0.1920904964208603, 0.06806664913892746, -0.04522404819726944, -0.030606256797909737, -0.019183160737156868, -0.15769758820533752, 0.057816021144390106, -0.2686406075954437, 0.01914249174296856, -0.24946972727775574, 0.04022407531738281, 0.10063797235488892, -0.056255824863910675, -0.07244429737329483, -0.03348565101623535, 0.11848832666873932, 0.011105290614068508, 0.11154654622077942, 0.035978902131319046, 0.008103253319859505, 0.08934415876865387, 0.025362921878695488, 0.048807621002197266, -0.03931545466184616, -0.078121617436409, 0.03694355487823486, -0.0769999548792839, -0.12144091725349426, 0.09219634532928467, 0.05615469813346863, -0.04786335304379463, -9.962457880874354e-08, 0.07155518233776093, -0.018570860847830772, -0.011871169321238995, -0.052600398659706116, 0.1036955863237381, -0.006960982456803322, 0.031769610941410065, -0.023276563733816147, 0.01750524714589119, 0.16848698258399963, 0.08542955666780472, 0.16232599318027496, -0.1835078001022339, 0.12011592090129852, -0.16203546524047852, 0.01607431098818779, -0.13942646980285645, -0.0256508719176054, -0.11739552766084671, -0.11777730286121368, -0.09648510068655014, 0.041665997356176376, -0.01458387728780508, -0.05346464365720749, -0.01113814301788807, 0.023242127150297165, 0.012923430651426315, -0.04712235927581787, -0.012105002999305725, 0.06780920177698135, -0.0018073210958391428, -0.11277694255113602, 0.011709719896316528, -0.009395943954586983, 0.002516297623515129, -0.00044164806604385376, -0.10611036419868469, 0.09634456038475037, 0.028966031968593597, 0.17921453714370728, -0.03517870232462883, -0.05395643785595894, -0.01225734781473875, 0.10415588319301605, 0.18391278386116028, -0.025649849325418472, -0.2902650237083435, -0.05472759157419205, 0.10821949690580368, -0.11379458010196686, -0.0019300095736980438, -0.04166810214519501, -0.09942689538002014, 0.01356613077223301, -0.06890027225017548, 0.07736009359359741, -0.0319039411842823, -0.07042057812213898, -0.011732151731848717, 0.08428262919187546, -0.017467383295297623, -0.24181199073791504, 0.059171292930841446, 0.019598744809627533], "changes": {"1wk": -2.076502006070814}}, {"text": "Calidi Biotherapeutics Announces Proposed Public Offering Calidi Biotherapeutics, Inc Thu, Jan 9, 2025, 12:01 AM 5 min read In This Article: CLDI +38.49% CLDWW +231.25% Calidi Biotherapeutics, Inc SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies,\u00a0today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (\u201cPre-Funded Warrants\u201d) in lieu thereof) in an public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company. Ladenburg\u00a0Thalmann\u00a0& Co. Inc. is acting as exclusive placement agent for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Calidi intends to use the net proceeds from the offering for working capital and for general corporate purposes. The securities described are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which was declared effective by the United States Securities and Exchange Commission (\u201cSEC\u201d) on October 10, 2024. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting\u00a0Ladenburg\u00a0Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com . Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi\u2019s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi\u2019s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi\u2019s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com . Story Continues Forward-Looking Statements This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company\u2019s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024, and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time. For Investors: Dave Gentry, CEO RedChip Companies, Inc. 1-407-644-4256 CLDI@redchip.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLDI", "date": "2025-01-08T21:01:00+00:00", "sentiment": {"score": -0.002390330657362938, "confidence": 0.024116631597280502, "probabilities": {"positive": 0.021726300939917564, "negative": 0.024116631597280502, "neutral": 0.9541570544242859}}, "embedding": [-0.15228751301765442, -0.078445203602314, -0.101763054728508, -0.04323894530534744, -0.05212916433811188, 0.03820931911468506, 0.001732073724269867, 0.11165540665388107, 0.19192570447921753, 0.07140618562698364, 0.15341438353061676, -0.005315972492098808, 0.033966097980737686, 0.026625489816069603, 0.013903792947530746, -0.15118074417114258, 0.030617497861385345, -0.006418677046895027, -0.08316577970981598, 0.15869373083114624, 0.015336329117417336, 0.017103008925914764, 0.00782953854650259, 0.039767321199178696, -0.028306428343057632, -0.06287616491317749, -0.10906034708023071, -0.011246904730796814, -0.16748446226119995, -0.012080872431397438, 0.05151345208287239, 0.08456439524888992, 0.10303665697574615, -0.026742422953248024, 0.11934138834476471, 0.042446114122867584, -0.13496701419353485, 0.00929450523108244, 0.013980932533740997, 0.03299644961953163, -0.0466911718249321, -0.11538200825452805, -0.04665713757276535, 0.1325552761554718, -0.07450691610574722, -0.07236973196268082, -0.06654567271471024, 0.1340206265449524, 0.0005932394415140152, 0.07945509254932404, -0.13933208584785461, -0.023041369393467903, -0.025074973702430725, 0.14172488451004028, -0.06540711969137192, -0.022249970585107803, -0.18829864263534546, -0.059951264411211014, -0.018593071028590202, 0.015340890735387802, 0.07103776186704636, -0.014937596395611763, -0.008193673565983772, 0.016537021845579147, 0.1022660881280899, 0.013658363372087479, 0.007203383836895227, -0.021759415045380592, 0.04399234056472778, -0.05263924598693848, 0.20322464406490326, -0.07256315648555756, -0.08562210202217102, 0.09607478976249695, -0.11629989743232727, 0.13269871473312378, 0.11664140969514847, 0.10729041695594788, 0.12375673651695251, -0.15082120895385742, 0.012039849534630775, 0.06316110491752625, -0.03702174872159958, -0.06399118155241013, -0.043844547122716904, 0.033787764608860016, 0.07874835282564163, 0.08518074452877045, 0.09667715430259705, -0.05126004293560982, 0.12617209553718567, -0.06795254349708557, -0.025422625243663788, -0.052876297384500504, -0.059252362698316574, -0.015364090912044048, -0.04977782815694809, 0.03739785775542259, -0.048079341650009155, 0.04370449110865593, 0.05428231507539749, -0.08401267230510712, -0.14528080821037292, -0.051792219281196594, -0.0971556305885315, -0.05642556771636009, -0.09633398056030273, 0.05532199516892433, -0.02306487038731575, 0.03070005774497986, -0.09901835024356842, 0.0780317634344101, -0.07249017804861069, 0.041777003556489944, -0.04273148626089096, 0.20675602555274963, 0.015173623338341713, 0.05064082890748978, 0.1516522467136383, -0.15446625649929047, 0.034122735261917114, 0.040743663907051086, -0.0274672694504261, -0.15316078066825867, -0.004176190122961998, -0.0993303656578064, -0.10952168703079224, 9.488651378606954e-33, 0.007705010008066893, 0.053637243807315826, 0.00029579363763332367, -0.01201267447322607, -0.0832248106598854, 0.006453981157392263, 0.0570165254175663, -0.01998232677578926, -0.12278713285923004, 0.01086697168648243, -0.13465851545333862, 0.15841907262802124, -0.010916532948613167, -0.0016106273978948593, -0.06002400070428848, -0.05833686888217926, 0.027071664109826088, 0.06682170927524567, 0.1905985176563263, -0.031669870018959045, 0.1228155866265297, 0.10599194467067719, -0.040581293404102325, 0.049216918647289276, -0.08247382193803787, 0.05800265818834305, -0.1485162079334259, -0.023418322205543518, -0.023963849991559982, 0.08243580162525177, 0.03868640586733818, 0.02950972318649292, 0.017446106299757957, -0.008763066492974758, 0.05037223547697067, 0.007569801062345505, -0.08854322880506516, -0.11468015611171722, -0.00958859920501709, 0.13192954659461975, -0.01455016154795885, 0.13222132623195648, 0.060559019446372986, -0.07006394118070602, 0.054960280656814575, -0.03937413915991783, -0.12047748267650604, 0.14552360773086548, 0.11899679899215698, 0.043963704258203506, -0.04407106712460518, 0.047821152955293655, -0.006557578220963478, -0.08504217863082886, -0.06495606154203415, 0.01554008387029171, -0.10010114312171936, -0.03374278545379639, -0.054505959153175354, 0.05574619024991989, 0.05274505168199539, 0.12626154720783234, -0.12069758772850037, -0.011956589296460152, -0.22570742666721344, -0.021700549870729446, -0.053728628903627396, -0.030912840738892555, -0.027029847726225853, 0.08029083907604218, -0.07706895470619202, 0.04500894248485565, 0.09392884373664856, 0.012876993976533413, 0.10836216807365417, -0.1342562437057495, 0.04368065670132637, 0.10558408498764038, 0.033923398703336716, -0.020724313333630562, -0.0014927536249160767, 0.044587671756744385, 0.012736700475215912, 0.1761602759361267, -0.03776833415031433, 0.02500533126294613, -0.004580178298056126, 0.08227208256721497, -0.005264908075332642, -0.007978980429470539, 0.03437729924917221, -0.03838612139225006, -0.13076260685920715, 0.10608695447444916, 0.02952340431511402, -9.460562941094055e-33, -0.009370764717459679, -0.16584870219230652, -0.004129089415073395, -0.038211118429899216, -0.0458315834403038, 0.037768661975860596, 0.07630909979343414, -0.0970146656036377, -0.004954345524311066, -0.1395171731710434, -0.008947860449552536, 0.010257490910589695, 0.01390488538891077, -0.07068941742181778, -0.06985022127628326, 0.07044552266597748, 0.0012343395501375198, -0.11013751477003098, -0.03380586579442024, 0.007222834974527359, -0.01568005047738552, 0.12279268354177475, -0.04374821111559868, 0.010330567136406898, 0.10229821503162384, -0.045448146760463715, 0.0885564312338829, 0.12283648550510406, 0.05594933032989502, 0.010295922867953777, -0.03303859755396843, -0.06945930421352386, -0.28389954566955566, 0.07745671272277832, -0.07335236668586731, -0.07555244863033295, 0.125546395778656, 0.0020312881097197533, -0.0063277073204517365, 0.028987906873226166, 0.11131329089403152, -0.038542475551366806, 0.03655696660280228, 0.12845799326896667, 0.0485585480928421, -0.11729932576417923, 0.11098568141460419, -0.01807555928826332, 0.11813158541917801, 0.11379086971282959, 0.009819157421588898, 0.007467764429748058, 0.042729854583740234, 0.0628698393702507, -0.07530476152896881, 0.05593356117606163, 0.01847429946064949, 0.010777302086353302, -0.06821382790803909, 0.017738517373800278, 0.10672912001609802, 0.13793227076530457, -0.023065390065312386, -0.033725231885910034, 0.20624896883964539, 0.02457326650619507, -0.07475608587265015, -0.025315068662166595, 0.028929565101861954, -0.11847394704818726, 0.0683295726776123, -0.2627548277378082, -0.031879276037216187, -0.2655967175960541, 0.03809927776455879, 0.034630920737981796, -0.08527766168117523, -0.09117230772972107, -0.10152141004800797, 0.10090769082307816, 0.01382554043084383, 0.10197973251342773, 0.018615741282701492, 0.0536322295665741, 0.11756595224142075, 0.0775776132941246, 0.05324159190058708, -0.05311693251132965, -0.010207310318946838, 0.015926919877529144, -0.06110012158751488, -0.09555664658546448, 0.05029485374689102, 0.09151169657707214, -0.07563191652297974, -9.956016810974688e-08, 0.05415026843547821, -0.007532809861004353, -0.0422159880399704, -0.051439374685287476, 0.15959233045578003, -0.012058300897479057, 0.03384685516357422, -0.06670653074979782, 0.022582750767469406, 0.1298561692237854, 0.10440082103013992, 0.14362946152687073, -0.17142635583877563, 0.027549032121896744, -0.0858599841594696, 0.008488437160849571, -0.07801365852355957, -0.012883571907877922, -0.13901424407958984, -0.07743190228939056, -0.09313751012086868, 0.024170244112610817, 0.006723364815115929, -0.07478158175945282, -0.00988820195198059, 0.021362099796533585, 0.031256597489118576, -0.07989850640296936, 0.021422896534204483, 0.11349037289619446, -0.037929367274045944, -0.08546780049800873, 0.03350677341222763, -0.048046037554740906, 0.007959660142660141, -0.0046902187168598175, -0.038555044680833817, 0.08247388154268265, 0.061233602464199066, 0.12706518173217773, -0.02169985882937908, 0.025326702743768692, -0.015418071299791336, 0.1285715103149414, 0.21210184693336487, -0.04276129603385925, -0.21484291553497314, -0.05205439031124115, 0.07859311997890472, -0.09071899205446243, -0.025434039533138275, -0.0843871608376503, -0.030690796673297882, 0.03152140974998474, -0.10256043076515198, 0.12856639921665192, 0.008608158677816391, -0.07718673348426819, 0.0066747358068823814, 0.039832327514886856, 0.02466540038585663, -0.2023790180683136, 0.16423021256923676, 0.06456451863050461], "changes": {"1wk": -32.14814871067208}}, {"text": "Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer Calidi Biotherapeutics, Inc Mon, Nov 18, 2024, 4:00 PM 5 min read In This Article: CLDI +38.49% CLDWW +231.25% Calidi Biotherapeutics, Inc SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (\u201cCalidi\u201d), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, presented data at the International Oncolytic Virotherapy Conference (IOVC) and the Society for Immunotherapy of Cancer (SITC) Annual Meeting to support the targeted capabilities of its proprietary RTNova\u2122 systemic enveloped virotherapy technology. This data supports the potential use of RTNova to target every metastatic site in multiple oncology indications including metastatic lung cancer. RTNova is uniquely designed to overcome key challenges in systemic virotherapy, including rapid immune clearance and limited therapeutic targeting. By incorporating enveloped technology into its tumor-selective vaccinia virus platform, RTNova now has the potential to target multiple metastatic tumor sites, killing and transforming, not one, but potentially all tumor microenvironments in the body. Calidi\u2019s enveloped virotherapies demonstrated robust therapeutic potential as a monotherapy and as a viral vector, allowing future expansion of functionality to support delivery of therapeutic gene or medicine payloads into all tumor sites. \u201cNew data presented at IOVC and SITC demonstrated the robust therapeutic potential of our RTNova technology in an advanced lung metastasis model,\u201d said Dr. Santidrian, Chief Scientific Officer of Calidi Biotherapeutics. \u201cThese findings represent a significant advancement in developing systemic antitumor virotherapy for advanced disease stages, which remains a leading cause of death in cancer patients. Additionally, the data reveals that once the virus reaches the tumors or metastases, it successfully kills and transforms tumor microenvironments and can additionally induce expression of engineered payloads in the tumor cells. We believe RTNova has the potential to transform how we address previously untreatable metastatic diseases.\u201d Download the poster presentation from SITC here . RTNova utilizes a novel, tumor-selective strain of vaccinia virus engineered to produce high levels of extracellular enveloped viruses (EEVs). These EEVs are designed to integrate human cell-derived proteins enabling the targeting of tumor sites while avoiding rapid clearance by the host immune system. This latest enhancement extends RTNova\u2019s utility, making it a versatile platform as a direct antitumor modality, and as a viral vector for customized delivery of cancer treatments. This data will also support the advancement of potential collaborative relationships with pharma partners. Story Continues Calidi Biotherapeutics continues to advance its clinical-stage, off-the-shelf, virotherapies. With RTNova, the company is planning multi-modal systemic antitumor virotherapies that can disrupt tumor growth, reprogram the tumor immune microenvironment, and achieve durable therapeutic outcomes for a larger patient population. About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi\u2019s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi\u2019s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi\u2019s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com . Forward-Looking Statements This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company\u2019s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024 and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time. For Investors: Dave Gentry, CEO RedChip Companies, Inc. 1-407-644-4256 CLDI@redchip.com Source: Calidi Biotherapeutics, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLDI", "date": "2024-11-18T13:00:00+00:00", "sentiment": {"score": 0.6405952107161283, "confidence": 0.6503173112869263, "probabilities": {"positive": 0.6503173112869263, "negative": 0.00972210057079792, "neutral": 0.33996060490608215}}, "embedding": [-0.012631526216864586, -0.05973551422357559, -0.1417303830385208, -0.15894103050231934, 0.09884535521268845, -0.1929960995912552, -0.07139987498521805, 0.01571544259786606, 0.2276541292667389, 0.10383188724517822, -0.10092325508594513, -0.08187439292669296, 0.1195826381444931, 0.1560104489326477, 0.1083451360464096, 0.03889020159840584, -0.04165171831846237, 0.11634551733732224, -0.12746132910251617, 0.15925593674182892, 0.06645897775888443, 0.12968602776527405, -0.04612733796238899, -0.02436140365898609, -0.07802821695804596, 0.04127643629908562, -0.1946713924407959, -0.05344449356198311, -0.2684360444545746, -0.042548857629299164, 0.08269602060317993, 0.042005352675914764, -0.0009388927137479186, 0.056409209966659546, -0.08549779653549194, -0.04408583045005798, -0.2313593626022339, 0.228253573179245, -0.2807638645172119, -0.1944516897201538, -0.06450516730546951, -0.055958978831768036, -0.06265559047460556, 0.11702863872051239, -0.09184503555297852, -0.20204152166843414, -0.2836206555366516, 0.006698290817439556, 0.09732886403799057, 0.3444203734397888, -0.16515225172042847, -0.01319778710603714, -0.19446614384651184, 0.4088432788848877, -0.09696789085865021, 0.15503722429275513, -0.15416522324085236, 0.045819543302059174, 0.08442434668540955, -0.09247642010450363, 0.040242750197649, -0.16118985414505005, 0.12158362567424774, -0.043478913605213165, 0.09725304692983627, -0.11921091377735138, -0.02310936711728573, 0.10091382265090942, -0.08240659534931183, 0.06154739856719971, 0.0037772133946418762, 0.09527179598808289, -0.03416862338781357, 0.24941198527812958, 0.034811705350875854, 0.1606418639421463, 0.23350271582603455, 0.12170445919036865, 0.24325138330459595, -0.006502749398350716, 0.1664406955242157, 0.13003279268741608, 0.03398177772760391, 0.08286674320697784, 0.05705522745847702, 0.10820424556732178, -0.02283329702913761, 0.10732828080654144, 0.06897790729999542, 0.06634073704481125, 0.10246451944112778, 0.1356479376554489, 0.11197875440120697, 0.04045967757701874, 0.042278043925762177, 0.03083213046193123, -0.047350574284791946, -0.031368520110845566, 0.009560035541653633, -0.039965011179447174, -0.14953476190567017, -0.14115457236766815, -0.15336638689041138, -0.038443513214588165, 0.0021638916805386543, -0.10192502290010452, -0.06962434202432632, -0.0037038284353911877, -0.13484306633472443, 0.026670830324292183, 0.12307461351156235, 0.07109269499778748, 0.06480187177658081, -0.11564864218235016, 0.15980976819992065, 0.35650143027305603, -0.1552368402481079, 0.05041896924376488, 0.032458316534757614, -0.1413779854774475, -0.15146276354789734, 0.02437792718410492, -0.09317761659622192, -0.11469864845275879, 0.07059646397829056, 0.0821654200553894, -0.15296322107315063, 8.792496440743132e-33, 0.09634119272232056, 0.07505800575017929, 0.13867583870887756, 0.2961650490760803, 0.030696945264935493, -0.21458300948143005, 0.1071673184633255, 0.009283685125410557, -0.21217304468154907, -0.10901759564876556, -0.05225149914622307, 0.06343747675418854, -0.03821253404021263, 0.18149691820144653, 0.0689833015203476, -0.15146413445472717, 0.0201876163482666, -0.008028791286051273, -0.03596070036292076, -0.1449793577194214, 0.11117082834243774, 0.0648035779595375, 0.021528001874685287, -0.08811909705400467, -0.15231536328792572, 0.08862540125846863, -0.10307306051254272, 0.093549445271492, 0.04813816398382187, 0.029418302699923515, -0.2643744945526123, 0.16251906752586365, 0.09918975830078125, 0.007721751928329468, 0.08394531160593033, -0.06167811527848244, -0.03309870511293411, -0.17303188145160675, -0.1393963098526001, 0.26167646050453186, 0.04142139106988907, 0.0986565351486206, -0.1684168130159378, -0.0792202576994896, 0.03405830264091492, -0.12470763921737671, -0.019070852547883987, 0.0981832891702652, -0.10503030568361282, 0.18414440751075745, 0.019946347922086716, -0.006000812165439129, 0.058590397238731384, -0.013146448880434036, -0.13210827112197876, 0.034594230353832245, -0.17782533168792725, -0.05950314551591873, 0.023200679570436478, -0.04108336567878723, -0.03686772659420967, -0.08613456040620804, 0.05897977575659752, 0.12095026671886444, -0.08282214403152466, 0.044602181762456894, 0.033092524856328964, -0.033648911863565445, -0.02836516872048378, 0.2526710629463196, -0.0712713748216629, 0.13769197463989258, 0.17775556445121765, -0.07758427411317825, 0.22562670707702637, 0.07969257235527039, 0.11127553880214691, 0.057454273104667664, -0.03962549939751625, 0.21057148277759552, -0.05268160253763199, 0.11767052859067917, -0.16081765294075012, 0.06249970197677612, -0.12073908001184464, -0.34751537442207336, 0.005332626402378082, -0.047955140471458435, -0.1131398156285286, -0.14206725358963013, 0.11742325127124786, -0.09512417763471603, 0.029019858688116074, 0.08267943561077118, -0.12832045555114746, -8.202126443561716e-33, 0.08345024287700653, -0.12332480400800705, 0.0430685356259346, 0.09152896702289581, -0.058124274015426636, 0.25395166873931885, 0.05224519968032837, -0.2766162157058716, -0.0458124615252018, -0.21400511264801025, 0.00010278169065713882, 0.03895017132163048, 0.05033260956406593, -0.12457728385925293, -0.10380306094884872, 0.024538811296224594, 0.07371270656585693, -0.18278034031391144, -0.18658626079559326, 0.007040244061499834, 0.002393585629761219, 0.21954499185085297, -0.0987657681107521, 0.12422491610050201, 0.01145971193909645, -0.13855263590812683, 0.19548217952251434, 0.017094170674681664, 0.09138895571231842, 0.008298743516206741, 0.06890925765037537, 0.04256346821784973, -0.16837015748023987, 0.06802122294902802, -0.05051523074507713, 0.13864226639270782, 0.2381698489189148, -0.26854661107063293, 0.11853908002376556, -0.1684628427028656, 0.08246034383773804, -0.12917514145374298, -0.22935788333415985, 0.0077063897624611855, -0.062073253095149994, 0.06341105699539185, 0.09710617363452911, 0.16588088870048523, 0.1785593032836914, 0.0350835956633091, 0.0381118543446064, -0.07101096212863922, -0.1648271679878235, 0.07750172913074493, -0.026988178491592407, 0.10431397706270218, -0.0027427151799201965, 0.0851605087518692, -0.006205720826983452, 0.043498579412698746, 0.014079160988330841, 0.026703698560595512, -0.02293969690799713, -0.1629115641117096, -0.014654293656349182, 0.2065938264131546, 0.1561480313539505, 0.017535623162984848, -0.043316878378391266, -0.14823417365550995, -0.029057471081614494, -0.12833671271800995, 0.08641502261161804, -0.0676446408033371, 0.09098836779594421, -0.01320711337029934, 0.14165903627872467, -0.20377162098884583, -0.12583863735198975, 0.11272180080413818, -0.01851770654320717, 0.032276738435029984, 0.045425500720739365, -0.1654128134250641, 0.27065205574035645, 0.19278813898563385, 0.010771466419100761, 0.11728613078594208, -0.09455761313438416, 0.13051441311836243, -0.08047955483198166, -0.12173396348953247, -0.08324355632066727, 0.17338618636131287, 0.07652683556079865, -1.0007833850522729e-07, 0.1920139491558075, 0.015463982708752155, -0.030245445668697357, -0.13878098130226135, -0.1598769724369049, 0.09210601449012756, 0.05912597104907036, 0.013105945661664009, -0.052498165518045425, 0.16574662923812866, 0.07447577267885208, -0.00024935032706707716, -0.09806397557258606, -0.033485569059848785, 0.18755656480789185, 0.15317516028881073, -0.0936436653137207, 0.0634685680270195, -0.15231840312480927, -0.13010765612125397, -0.09498779475688934, 0.06310498714447021, -0.08011172711849213, -0.19432154297828674, 0.07984907925128937, -0.0966813713312149, -0.11836834996938705, -0.030428187921643257, 0.04862000793218613, -0.16272079944610596, -0.172138512134552, -0.14309537410736084, -0.12681670486927032, -0.1182607114315033, -0.13316583633422852, 0.11907580494880676, 0.04169541224837303, -0.14110074937343597, 0.08900254964828491, 0.23637646436691284, 0.15592050552368164, 0.07747972756624222, -0.16086912155151367, -0.052262891083955765, -0.10662425309419632, 0.08387599885463715, -0.2028598189353943, -0.006584149785339832, -0.1637728214263916, 0.04813835024833679, -0.03074631281197071, -0.03660915791988373, -0.013073280453681946, -0.023151692003011703, -0.07727152109146118, 0.373685359954834, -0.07985690236091614, -0.15066936612129211, 0.10269761830568314, 0.05648823082447052, 0.016696475446224213, -0.09453986585140228, 0.14782066643238068, -0.08898743987083435], "changes": {"1wk": -8.936162053216247, "1mo": -26.382974924248835}}, {"text": "Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock Calidi Biotherapeutics, Inc Thu, Nov 14, 2024, 4:30 PM 4 min read In This Article: CLDI +38.49% CLDWW +231.25% Calidi Biotherapeutics, Inc SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies,\u00a0today announced that it has priced its public offering of 4,437,869 shares of the Company\u2019s common stock at a price of $1.69 per share. The closing of the offering is expected to occur on or about November 15, 2024, subject to the satisfaction of customary closing conditions. Ladenburg\u00a0Thalmann\u00a0& Co. Inc. is acting as exclusive placement agent for the offering. The gross proceeds to Calidi from the offering, before deducting the placement agent fees and other offering expenses payable by the Company, are expected to be\u00a0approximately $7.5 million. Calidi intends to use the net proceeds from the offerings for working capital and for general corporate purposes and pre-clinical and clinical trials. The securities described above (excluding the warrants and the shares of common stock underlying the warrants) are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which was declared effective by the United States Securities and Exchange Commission (\u201cSEC\u201d) on October 10, 2024. The registered direct offering is being made only by means of a prospectus, including a prospectus supplement, which is part of the effective registration statement, that will be filed with the SEC.\u00a0Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC\u2019s website at http://www.sec.gov\u00a0or by contacting\u00a0Ladenburg\u00a0Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi\u2019s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi\u2019s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi\u2019s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com . Story Continues Forward-Looking Statements This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company\u2019s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024 and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time. For Investors: Dave Gentry, CEO RedChip Companies, Inc. 1-407-644-4256 CLDI@redchip.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLDI", "date": "2024-11-14T13:30:00+00:00", "sentiment": {"score": 0.0008108783513307571, "confidence": 0.021992625668644905, "probabilities": {"positive": 0.021992625668644905, "negative": 0.021181747317314148, "neutral": 0.9568256139755249}}, "embedding": [-0.08735848218202591, -0.09051920473575592, -0.12531550228595734, -0.0054649896919727325, -0.046883173286914825, 0.007206955924630165, 0.04356278479099274, 0.15656843781471252, 0.240109384059906, 0.08513705432415009, 0.09739415347576141, -0.08380593359470367, 0.009596019051969051, 0.06116460636258125, -0.019146401435136795, -0.10930443555116653, 0.024913663044571877, 0.022264819592237473, -0.09870263189077377, 0.15076899528503418, 0.005993600934743881, 0.0005163578316569328, 0.01723976992070675, 0.06370571255683899, -0.020017363131046295, -0.05160076916217804, -0.06089794635772705, -0.01643015444278717, -0.17987799644470215, -0.03281912952661514, 0.04022209346294403, 0.024120932444930077, 0.07277513295412064, -0.047829531133174896, 0.13457882404327393, 0.04481113702058792, -0.13217994570732117, 0.03006763383746147, -0.024210678413510323, 0.07341232895851135, -0.06758186221122742, -0.050232335925102234, -0.09792884439229965, 0.0952225774526596, -0.03921130672097206, -0.105332151055336, -0.09462864696979523, 0.1640007346868515, 0.04971054196357727, 0.12635640799999237, -0.1098661944270134, -0.017734229564666748, -0.04585089534521103, 0.11774861812591553, -0.04255591332912445, -0.04455815255641937, -0.15210983157157898, -0.08084392547607422, 0.0013991245068609715, 0.02919931150972843, 0.02326333522796631, -0.04025358334183693, -0.03756146878004074, 0.01405254378914833, 0.11019450426101685, -0.010279066860675812, -0.008127499371767044, -0.052606187760829926, 0.021522702649235725, -0.042885296046733856, 0.17016929388046265, -0.03979680687189102, -0.009720874950289726, 0.07224133610725403, -0.0766981840133667, 0.1208350732922554, 0.13644888997077942, 0.08741104602813721, 0.11373378336429596, -0.06573337316513062, 0.045871712267398834, 0.022499505430459976, -0.033523958176374435, -0.03780842572450638, 0.017586510628461838, 0.013527466915547848, 0.11928468197584152, 0.13885080814361572, 0.12015753239393234, -0.015331778675317764, 0.13782823085784912, -0.022733157500624657, -0.027962341904640198, -0.05985473468899727, -0.044811002910137177, 0.033658236265182495, -0.05725397914648056, 0.013091162778437138, -0.05037582665681839, 0.023360786959528923, 0.032040785998106, -0.06990334391593933, -0.09525918960571289, -0.06452742218971252, -0.06855788826942444, -0.06492223590612411, -0.04862459748983383, 0.022430509328842163, -0.019051047042012215, 0.005483041983097792, -0.11638228595256805, 0.024204067885875702, -0.08838865906000137, 0.03253753483295441, -0.046708591282367706, 0.23843571543693542, 0.042094770818948746, 0.012643083930015564, 0.18429255485534668, -0.12292706966400146, 0.03594190254807472, 0.010091381147503853, -0.016546808183193207, -0.13235658407211304, -0.014932902529835701, -0.06216924265027046, -0.08256544172763824, 9.629649721936179e-33, -0.018908973783254623, 0.042254164814949036, -0.006651559844613075, -0.01986571028828621, -0.08083125948905945, -0.015300027094781399, 0.06710298359394073, -0.008539382368326187, -0.11029490828514099, 0.022705189883708954, -0.1485782265663147, 0.12695740163326263, -0.019165944308042526, 0.02899460680782795, -0.043416716158390045, -0.07601437717676163, 0.01754717156291008, 0.03541240096092224, 0.17996883392333984, -0.03449178859591484, 0.08776949346065521, 0.11679947376251221, -0.05628623813390732, 0.058810628950595856, -0.11468960344791412, 0.11301401257514954, -0.14249449968338013, -0.024551644921302795, 0.019828906282782555, 0.057063765823841095, -0.007908382453024387, 0.017272667959332466, 0.060296423733234406, -0.015569987706840038, 0.03271615505218506, 0.0062956735491752625, -0.059559036046266556, -0.10986659675836563, 0.05861619859933853, 0.15885984897613525, -0.026235459372401237, 0.13456396758556366, 0.06602855026721954, -0.09615574777126312, 0.01749095506966114, -0.044598180800676346, -0.0725155621767044, 0.12845934927463531, 0.08893396705389023, 0.04083156958222389, -0.08179233968257904, 0.07139047980308533, -0.0032238364219665527, -0.04776494950056076, -0.08554723858833313, -0.03296515345573425, -0.07872292399406433, -0.0708872377872467, -0.0230324175208807, 0.07481488585472107, 0.020245332270860672, 0.1459999829530716, -0.06340046972036362, 0.0024576671421527863, -0.2006097435951233, -0.004909337963908911, -0.0890500396490097, -0.054562002420425415, -0.00545869767665863, 0.10741210728883743, -0.06059987097978592, 0.027564819902181625, 0.13701747357845306, -0.04256940633058548, 0.1284548044204712, -0.11815670877695084, 0.06093655899167061, 0.08177833259105682, 0.08035515993833542, 0.012386955320835114, 0.060495682060718536, 0.0543227456510067, -0.017313461750745773, 0.1732797771692276, -0.027356645092368126, 0.0175635889172554, -0.06995551288127899, 0.06769060343503952, -0.07349945604801178, -0.0009637814946472645, 0.06443128734827042, -0.04376800358295441, -0.10309979319572449, 0.06911516189575195, -0.003378394991159439, -8.47607540202085e-33, -0.041765227913856506, -0.09891074895858765, 0.017889708280563354, -0.018995948135852814, -0.04781067371368408, 0.05527326464653015, 0.0686345025897026, -0.10220298171043396, 0.014012672007083893, -0.06833909451961517, -0.017178840935230255, 0.05083032324910164, 0.01354430802166462, -0.043868713080883026, -0.07809562981128693, 0.08718550205230713, -0.020467743277549744, -0.08477217704057693, -0.008661508560180664, -0.07080136984586716, -0.03415877744555473, 0.20752547681331635, -0.035011567175388336, 0.012399883009493351, 0.10239969938993454, -0.014109188690781593, 0.09766408801078796, 0.1071312204003334, 0.11450508236885071, 0.039689257740974426, -0.06550829112529755, -0.0751083642244339, -0.2506300210952759, 0.05274781212210655, -0.0703732967376709, -0.021093910560011864, 0.13654924929141998, -0.0003591817803680897, -0.0060630980879068375, -0.0037732641212642193, 0.0510554239153862, -0.08307778835296631, 0.021450858563184738, 0.08324138820171356, 0.1449993997812271, -0.13467997312545776, 0.06389214098453522, -0.04267244040966034, 0.14795008301734924, 0.13661175966262817, -0.06576654314994812, -0.0046520656906068325, -0.02688688412308693, 0.07133837789297104, -0.1287761628627777, 0.05353759974241257, 0.015112591907382011, 0.029606420546770096, -0.0423232726752758, -0.025633808225393295, 0.09243809431791306, 0.12722763419151306, -0.01833205111324787, -0.01048213429749012, 0.1802903562784195, 0.07580171525478363, -0.033713631331920624, -0.01756097935140133, -0.018746748566627502, -0.15409865975379944, 0.02197110839188099, -0.24932655692100525, 0.04097752273082733, -0.2563161849975586, 0.043790727853775024, 0.06204576790332794, -0.052156105637550354, -0.07197612524032593, -0.039075858891010284, 0.10378358513116837, 0.006899098865687847, 0.06371273100376129, 0.019024131819605827, 0.024418536573648453, 0.0589306615293026, 0.029340291395783424, 0.07263263314962387, -0.020324140787124634, -0.0836019441485405, 0.06631945818662643, -0.06333469599485397, -0.09741009771823883, 0.0877656489610672, 0.06710884720087051, -0.057134319096803665, -9.927654787134088e-08, 0.06375790387392044, -0.02896968275308609, 0.02286224626004696, -0.07946284860372543, 0.1432485729455948, -0.02546684443950653, 0.0268850214779377, -0.021018683910369873, 0.007548791356384754, 0.16472220420837402, 0.12098301947116852, 0.1696470081806183, -0.16366852819919586, 0.09330379217863083, -0.12936939299106598, 0.029488610103726387, -0.128824383020401, -0.01604015752673149, -0.10643486678600311, -0.11092060804367065, -0.10465976595878601, 0.04454081505537033, 0.014806783758103848, -0.07818061113357544, -0.01204446516931057, 0.010099206119775772, 0.02360568940639496, -0.027801958844065666, 0.00526244193315506, 0.06054515391588211, -0.003740343963727355, -0.08542073518037796, 0.025802940130233765, -0.030895914882421494, -0.0077672116458415985, -0.00019090180285274982, -0.0862254947423935, 0.10404206067323685, 0.04012730345129967, 0.16007313132286072, -0.03476008027791977, -0.014298115856945515, -0.02696550264954567, 0.10644608736038208, 0.19194141030311584, -0.03299105539917946, -0.27273496985435486, -0.04003150761127472, 0.06990393996238708, -0.10300397872924805, 0.0004667285829782486, -0.037873364984989166, -0.07791735231876373, 0.013956086710095406, -0.07683742046356201, 0.07806574553251266, -0.0004969043657183647, -0.07716348022222519, -0.008729062043130398, 0.05377975106239319, -0.002085035666823387, -0.22998973727226257, 0.08006678521633148, 0.02674800716340542], "changes": {"1wk": 13.930346901406562, "1mo": -7.960197382116542}}, {"text": "Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock Calidi Biotherapeutics, Inc Sat, Nov 16, 2024, 12:05 AM 4 min read In This Article: CLDI +38.49% CLDWW +231.25% Calidi Biotherapeutics, Inc SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (\u201cCalidi\u201d), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 4,437,869 shares of common stock at $1.69 per share for gross proceeds of approximately $7.5 million. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this offering. The securities described above public offering were offered pursuant to registration statements on Form S-3 (File No. 333-282456), which were declared effective by the United States Securities and Exchange Commission (\"SEC\") on October 10, 2024. The offering was made solely by means of a prospectus. A final prospectus relating to the offering was filed with the SEC on November 15, 2024, and is available on the SEC's website located at http://www.sec.gov . Copies of the final prospectus can be obtained at the SEC's website at http://www.sec.gov or from Ladenburg Thalmann & Co. Inc. Electronic copies of the final prospectus relating to the offering may be obtained, when available, from Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, New York 10019, or by telephone at (212) 409-2000, or by email at prospectus@ladenburg.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi\u2019s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi\u2019s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi\u2019s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com . Story Continues Forward-Looking Statements This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company\u2019s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024 and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time. For Investors: Dave Gentry, CEO RedChip Companies, Inc. 1-407-644-4256 CLDI@redchip.com Source: Calidi Biotherapeutics, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLDI", "date": "2024-11-15T21:05:00+00:00", "sentiment": {"score": -0.0052757058292627335, "confidence": 0.02508671209216118, "probabilities": {"positive": 0.019811006262898445, "negative": 0.02508671209216118, "neutral": 0.955102264881134}}, "embedding": [-0.0577118955552578, -0.15582981705665588, -0.1717076599597931, -0.08243668079376221, -0.09633690118789673, -0.015540679916739464, 0.042674385011196136, 0.16526907682418823, 0.23617245256900787, 0.05318508297204971, 0.1026727706193924, -0.03400397673249245, 0.0017674323171377182, 0.04221361503005028, -0.034772370010614395, -0.08473280072212219, 0.05494089424610138, 0.0068502482026815414, -0.08553522080183029, 0.2564394474029541, 0.043866731226444244, 0.005202683620154858, 0.0355282798409462, 0.051501646637916565, -0.0342336930334568, -0.02625393494963646, -0.08612950891256332, -0.04258451610803604, -0.23201045393943787, -0.013950878754258156, 0.0389525443315506, 0.019135547801852226, 0.1477852165699005, -0.03886899724602699, 0.1408090591430664, 0.08212290704250336, -0.12924009561538696, 0.05114303529262543, -0.015332357957959175, 0.06469491124153137, -0.08238397538661957, -0.07212300598621368, -0.07308880984783173, 0.11822006106376648, -0.08249518275260925, -0.08337005227804184, -0.17529678344726562, 0.16192224621772766, 0.05707197263836861, 0.19450676441192627, -0.11611149460077286, -0.018334340304136276, -0.053742311894893646, 0.14283715188503265, -0.046352773904800415, -0.05881435424089432, -0.13554716110229492, -0.034763067960739136, -0.014297385700047016, 0.05623357370495796, 0.07597716152667999, -0.01628240942955017, -0.010372262448072433, 0.05583169311285019, 0.10858111083507538, -0.03780530020594597, -0.00563065754249692, -0.07112313061952591, 0.016210200265049934, -0.16308540105819702, 0.20256730914115906, -0.062121473252773285, -0.009479278698563576, 0.12973730266094208, -0.10755860805511475, 0.1256343126296997, 0.16505306959152222, 0.1330852508544922, 0.10988016426563263, -0.0691303163766861, 0.06244184076786041, 0.07386551052331924, -0.028531212359666824, -0.022628124803304672, -0.019961310550570488, 0.09235652536153793, 0.12863293290138245, 0.16873663663864136, 0.12765324115753174, -0.059364572167396545, 0.11135049164295197, 0.032140906900167465, -0.009530643932521343, -0.07364179193973541, -0.09710074961185455, -0.042339153587818146, -0.030984913930296898, 0.029954470694065094, -0.06734619289636612, -0.002445490565150976, -0.008472365327179432, -0.07858017832040787, -0.1681559681892395, -0.10033431649208069, -0.08956818282604218, -0.05718979239463806, -0.06006035953760147, 0.05000657960772514, -0.0511355847120285, 0.028527256101369858, -0.1122334748506546, 0.10660731792449951, -0.06270039081573486, 0.0248354971408844, -0.0378161296248436, 0.23119211196899414, -0.04006418213248253, 0.027533940970897675, 0.23562757670879364, -0.14993324875831604, 0.016904886811971664, 0.04606582969427109, -0.09464094787836075, -0.18556708097457886, -0.003918909467756748, -0.035834718495607376, -0.10176198929548264, 9.935713186059778e-33, -0.0433947890996933, 0.014715840108692646, 0.004130343906581402, -0.012748472392559052, -0.07551953941583633, -0.017578482627868652, 0.11086677014827728, -0.03247751668095589, -0.17789435386657715, 0.00380655936896801, -0.14558738470077515, 0.13327157497406006, 0.017224116250872612, 0.055062927305698395, -0.01786954328417778, -0.06427881121635437, 0.05527570843696594, -1.1381693184375763e-05, 0.18274086713790894, -0.06671211868524551, 0.08514278382062912, 0.19164535403251648, -0.011318739503622055, 0.09310410171747208, -0.09595800191164017, 0.09841586649417877, -0.19751927256584167, -0.014438475482165813, 0.038359228521585464, 0.059909574687480927, -0.02907908335328102, 0.0019868705421686172, 0.08376321941614151, 0.011290761642158031, 0.07568366825580597, 0.04411087930202484, -0.05880340561270714, -0.14460831880569458, 0.02580706775188446, 0.14207009971141815, -0.026243720203638077, 0.1588936746120453, -0.024942241609096527, -0.09031715244054794, 0.07973359525203705, -0.0483013391494751, -0.08285914361476898, 0.1654757708311081, 0.10028316080570221, 0.03613024204969406, -0.08076673001050949, 0.1012503132224083, -0.021812111139297485, -0.05375182256102562, -0.08918474614620209, -0.004249788820743561, -0.0977260023355484, -0.09436561167240143, -0.07547733187675476, 0.08053303509950638, 0.05174940451979637, 0.19246962666511536, -0.04182687774300575, -0.043090108782052994, -0.22451159358024597, -0.08248049765825272, -0.0670851320028305, -0.10721297562122345, -0.011653018184006214, 0.14264363050460815, -0.111469566822052, 0.02775103785097599, 0.19798946380615234, 0.015358839184045792, 0.13757839798927307, -0.13453584909439087, 0.023921513929963112, 0.10281025618314743, 0.08066441863775253, -0.004023691639304161, 0.08716940134763718, 0.0762597993016243, 0.013121135532855988, 0.1745295524597168, 0.02001907117664814, 0.015825660899281502, -0.00448944978415966, 0.09584451466798782, -0.11992893368005753, 0.000686712097376585, -0.013116558082401752, -0.07130877673625946, -0.13164739310741425, 0.09225225448608398, -0.016726305708289146, -1.0317896521554844e-32, -0.015142526477575302, -0.19101816415786743, 0.061199888586997986, -0.04137479513883591, -0.12465247511863708, 0.06839056313037872, 0.056347090750932693, -0.11485934257507324, -0.037489861249923706, -0.09642687439918518, 0.043904587626457214, 0.04884342476725578, 0.08025075495243073, -0.04552053287625313, -0.04335225746035576, 0.1453690528869629, -0.033456653356552124, -0.09813280403614044, -0.03808198124170303, -0.04849110171198845, 0.02732992358505726, 0.17259320616722107, -0.018014267086982727, -0.001303626224398613, 0.10013603419065475, -0.09185139834880829, 0.11371143162250519, 0.11056656390428543, 0.11567476391792297, -0.020945308730006218, -0.07389431446790695, -0.08989356458187103, -0.3055505156517029, 0.14065131545066833, -0.0695682168006897, -0.05844264104962349, 0.09520047903060913, -0.06967438757419586, 0.05208312347531319, -0.03161798045039177, 0.015775129199028015, -0.09177074581384659, 0.011529719457030296, 0.08553222566843033, 0.10401476919651031, -0.10141010582447052, 0.05392614006996155, 0.0400647334754467, 0.13232183456420898, 0.09604868292808533, -0.08228861540555954, -0.013317827135324478, 0.001952496124431491, 0.04443591833114624, -0.09289278835058212, 0.04261977970600128, -0.013870339840650558, 0.016953887417912483, -0.06401603668928146, -0.05106454715132713, 0.10057563334703445, 0.15591785311698914, -0.009599734097719193, 0.012288459576666355, 0.20945867896080017, 0.10419332981109619, -0.04072566330432892, -0.008630529046058655, -0.05200846493244171, -0.18792082369327545, 0.05736984312534332, -0.2332324981689453, -0.0063394540920853615, -0.28661733865737915, 0.015225172974169254, 0.06466075032949448, -0.11805456131696701, -0.10124039649963379, -0.106037437915802, 0.18291406333446503, 0.035765282809734344, 0.09816640615463257, 0.03070800006389618, 0.06565500050783157, 0.12839637696743011, 0.13870099186897278, 0.034075986593961716, -0.05046737939119339, -0.04923355579376221, 0.033363908529281616, -0.09536311775445938, -0.10768413543701172, 0.05223921313881874, 0.03138180449604988, -0.04161541908979416, -9.944309908860305e-08, 0.09852766990661621, -0.004632872994989157, 0.027143094688653946, -0.10431766510009766, 0.1184503361582756, 0.0030309478752315044, -0.031877271831035614, -0.033058956265449524, 0.002047566697001457, 0.19841307401657104, 0.10104936361312866, 0.18519647419452667, -0.20805317163467407, 0.07435630261898041, -0.14812174439430237, -0.01199245173484087, -0.08832604438066483, 0.0019564200192689896, -0.04882609471678734, -0.07595756649971008, -0.11066362261772156, 0.013641389086842537, 0.04599738121032715, -0.0459059476852417, -0.03819819912314415, 0.0032007950358092785, -0.01968761906027794, -0.08851249516010284, -0.025056956335902214, 0.06569161266088486, 0.049564462155103683, -0.13629098236560822, 0.05149943754076958, -0.04379543662071228, -9.112153202295303e-05, -0.012689908035099506, -0.07802833616733551, 0.1055976003408432, 0.072696752846241, 0.21451544761657715, 0.030578741803765297, -0.05057043954730034, -0.019987894222140312, 0.10450668632984161, 0.17219731211662292, 0.02764333039522171, -0.24392101168632507, -0.09029977023601532, 0.10536807775497437, -0.12280753254890442, 0.02375856228172779, -0.12381228804588318, -0.10196157544851303, -0.038573917001485825, -0.11786182969808578, 0.12575595080852509, -0.04939170926809311, -0.09674525260925293, -0.007106207311153412, 0.06947273015975952, -0.02685435488820076, -0.22359901666641235, 0.14207112789154053, 0.06177468225359917], "changes": {"1wk": -2.283102785839374, "1mo": -15.52511527374698}}, {"text": "PREMIUM Top Midday Decliners MT Newswires Thu, Nov 14, 2024, 10:37 PM 1 min read In This Article: BRAG +5.48% Top Midday Decliners PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLDI", "date": "2024-11-14T19:37:53+00:00", "sentiment": {"score": 0.027441533282399178, "confidence": 0.04468701779842377, "probabilities": {"positive": 0.04468701779842377, "negative": 0.01724548451602459, "neutral": 0.9380675554275513}}, "embedding": [-0.08392538875341415, -0.02421478182077408, 0.1840360164642334, 0.1685631424188614, 0.14929307997226715, -0.0240801852196455, 0.03128795325756073, 0.0907876193523407, -0.07501816749572754, 0.017778731882572174, -0.11103525012731552, 0.0794624611735344, 0.015534918755292892, 0.03266148269176483, 0.08733237534761429, -0.09954759478569031, 0.13116812705993652, -0.1310701221227646, 0.029233867302536964, 0.005121238995343447, -0.14491404592990875, -0.0031525432132184505, -0.02862386591732502, 0.09572099894285202, 0.2134074717760086, -0.08669931441545486, -0.1049448698759079, 0.1015315130352974, 0.018413543701171875, -0.023721372708678246, -0.12827564775943756, -0.010157269425690174, 0.08516083657741547, -0.034129489213228226, -0.11773651093244553, -0.06876973807811737, 0.06317178159952164, -0.05255627632141113, -0.01188671961426735, 0.04588371515274048, 0.1524297297000885, -0.23019634187221527, -0.0995672419667244, -0.09935860335826874, -0.07126503437757492, -0.04249133542180061, 0.03217926621437073, 0.07993719726800919, -0.04369097575545311, 0.16754525899887085, 0.04625854641199112, 0.035625819116830826, 0.04074490815401077, -0.16240210831165314, -0.015108278952538967, -0.05409890040755272, -0.14290481805801392, -0.1436973661184311, 0.050182536244392395, -0.005723453592509031, -0.10304804146289825, -0.07843532413244247, -0.20542001724243164, 0.05559055507183075, 0.06114356219768524, 0.11752703040838242, -0.03337005153298378, 0.38450631499290466, -0.03898211196064949, -0.1731386035680771, 0.017435017973184586, 0.052987705916166306, 0.022604433819651604, 0.0878826454281807, 0.07581667602062225, 0.029286859557032585, 0.23863978683948517, -0.16341866552829742, 0.07722237706184387, -0.043815579265356064, -0.012671271339058876, -0.07633110135793686, 0.03183723986148834, -0.09204404056072235, -0.04640087112784386, -0.0867636427283287, 0.12467177212238312, 0.015621483325958252, -0.05368523299694061, -0.2523497939109802, 0.07380075007677078, 0.09019354730844498, -0.049802009016275406, 0.05297579616308212, -0.08528075367212296, 0.08384666591882706, -0.2157595008611679, -0.16269700229167938, -0.19969701766967773, 0.1045236885547638, 0.04005596414208412, 0.06496251374483109, -0.06061680614948273, -0.027058981359004974, 0.07080839574337006, -0.15123189985752106, -0.15855184197425842, 0.24053730070590973, 0.041611794382333755, 0.0734073668718338, 0.005600296426564455, 0.060211822390556335, 0.09094998985528946, -0.19387736916542053, 0.05533317103981972, 0.05585481971502304, -0.13030293583869934, -0.03559952601790428, 0.11421248316764832, 0.0024079063441604376, 0.03067241795361042, 0.11241819709539413, -0.02529490552842617, 0.03324955701828003, 0.125510111451149, 0.07301274687051773, 0.06922653317451477, 1.6327124294662167e-32, 0.07975748181343079, 0.03768007084727287, 0.11100874096155167, -0.15031231939792633, 0.09356576949357986, -0.014978278428316116, -0.07713524252176285, -0.011063643731176853, 0.007677957881242037, -0.018489684909582138, -0.08303015679121017, 0.1495543122291565, -0.06781483441591263, 0.02523619681596756, -0.10169848799705505, -0.27799761295318604, 0.08038924634456635, 0.11072660237550735, 0.0010389767121523619, 0.018579769879579544, -0.06910679489374161, -0.1011265218257904, -0.09901770949363708, 0.008932439610362053, -0.0974854975938797, 0.14596746861934662, 0.10230883955955505, -0.045680832117795944, 0.1951657235622406, 0.09946920722723007, 0.0024280196521431208, -0.08144515007734299, -0.022282583639025688, -0.026323692873120308, 0.044075191020965576, 0.10117616504430771, -0.07368313521146774, 0.004112350754439831, -0.0550350658595562, -0.2095450907945633, -0.031442973762750626, -0.037823405116796494, -0.2420470118522644, 0.034434203058481216, -0.08729099482297897, 0.021682091057300568, 0.1635296493768692, -0.17556343972682953, -0.039983171969652176, -0.08878228068351746, -0.0689241960644722, 0.10565001517534256, -0.18699082732200623, 0.0467517226934433, -0.027177222073078156, 0.10500708222389221, -0.0051123034209012985, -0.14358395338058472, 0.14149843156337738, -0.07120955735445023, 0.18845413625240326, 0.020363273099064827, 0.019747819751501083, -0.1432105451822281, -0.11150132864713669, 0.012301122769713402, 0.010088943876326084, 0.011308345012366772, -0.11327571421861649, 0.12235129624605179, 0.23451711237430573, 0.04076739028096199, 0.04247415438294411, 0.02872372418642044, 0.015689492225646973, 0.1756659746170044, 0.12189023941755295, 0.03655972704291344, 0.21861997246742249, 0.03295833617448807, 0.15903396904468536, -0.0036357275675982237, 0.16915401816368103, -0.09609092026948929, 0.12701456248760223, 0.13473044335842133, 0.15122486650943756, -0.19392293691635132, -0.005264251958578825, 0.08170083165168762, -0.17658992111682892, 0.09369754791259766, -0.011789717711508274, 0.1249123141169548, -0.1423054337501526, -1.5052021491287076e-32, -0.1259566694498062, 0.042690571397542953, -0.026841385290026665, 0.06117122247815132, -0.09559430927038193, -0.0651397779583931, 0.0522615872323513, 0.12928859889507294, 0.14362318813800812, 0.126180037856102, 0.030426710844039917, 0.016095999628305435, -0.04965745285153389, -0.0026338419411331415, 0.08002254366874695, -0.10037204623222351, 0.2671513259410858, -0.05814942345023155, -0.24040833115577698, -0.006777484435588121, -0.03518830984830856, 0.06019909679889679, -0.21514201164245605, 0.08204830437898636, 0.17006349563598633, 0.04472007229924202, 0.03986956179141998, 0.14372824132442474, 0.06195187568664551, -0.061371222138404846, -0.12662844359874725, 0.05574460327625275, -0.04942366108298302, -0.055955205112695694, -0.05630813539028168, 0.041099388152360916, 0.10499688982963562, 0.20081563293933868, -0.11712314933538437, -0.013587257824838161, 0.14020703732967377, -0.03332359343767166, 0.01905742846429348, 0.006259740795940161, 0.01465599611401558, 0.07589472085237503, -0.04611730948090553, -0.024092596024274826, 0.0014742775820195675, 0.008116215467453003, -0.05248128995299339, -0.025658385828137398, 0.04995983466506004, 0.2540387511253357, -0.0998605415225029, 0.05118129029870033, -0.0004475326568353921, -0.05997757986187935, 0.12936720252037048, 0.018308769911527634, 0.002737282309681177, 0.07089409232139587, -0.16163180768489838, -0.06436572968959808, 0.1125294640660286, -0.036406900733709335, 0.10879857838153839, -0.19355612993240356, -0.09977337718009949, 0.01486347708851099, 0.07391150295734406, -0.01231527328491211, -0.01772748865187168, -0.33804869651794434, -0.03446631506085396, 0.16378971934318542, -0.03981563821434975, 0.2045661360025406, -0.14263883233070374, -0.06655144691467285, -0.009517267346382141, 0.010135520249605179, -0.18758521974086761, -0.10348924994468689, -0.09094781428575516, -0.07745566219091415, 0.18055929243564606, -0.08871614187955856, -0.1379995197057724, 0.011927864514291286, -0.14914670586585999, -0.09276266396045685, -0.1975238174200058, 0.08111352473497391, -0.010617630556225777, -9.959567393025281e-08, 0.05448436737060547, -0.034831080585718155, -0.09396737068891525, -0.03458257392048836, 0.10102511197328568, 0.10958895832300186, 0.034979961812496185, -0.09317439049482346, 0.03845743462443352, 0.21332623064517975, 0.1160791665315628, -0.11016197502613068, -0.0370846651494503, -0.08314236998558044, 0.008223149925470352, -0.07543811202049255, -0.03379886969923973, -0.11904862523078918, -0.0421781986951828, -0.19915474951267242, 0.14589093625545502, 0.10016345232725143, 0.16649240255355835, -0.14364103972911835, 0.10467121005058289, 0.025707976892590523, -0.01866297982633114, 0.11335217952728271, 0.07133912295103073, -0.02113514021039009, -0.1028321236371994, 0.13303756713867188, -0.20971469581127167, -0.20848692953586578, 0.1874900758266449, 0.2090180516242981, -0.11272845417261124, 0.09454338252544403, 0.04018512740731239, 0.04951107129454613, -0.015849994495511055, -0.22870616614818573, 0.07988431304693222, 0.09189961105585098, -0.012405983172357082, -0.054126348346471786, -0.08918745815753937, -0.07673296332359314, 0.17310577630996704, -0.17280514538288116, 0.03190561756491661, -0.12602461874485016, 0.23426584899425507, -0.00045554814278148115, 0.07152222841978073, 0.05675332248210907, 0.1003699004650116, -0.19504304230213165, -0.2050986886024475, 0.09718713909387589, 0.14253373444080353, -0.22607968747615814, -0.25065457820892334, 0.1126597449183464], "changes": {"1wk": 6.965179381513735, "1mo": -7.960197382116542}}, {"text": "Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results Calidi Biotherapeutics, Inc Wed, Nov 13, 2024, 1:29 AM 7 min read In This Article: CLDI +38.49% CLDWW +231.25% Calidi Biotherapeutics, Inc Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma. Presented data supporting RTNova (CLD-400), the company\u2019s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and at Immuno US 2024 in San Diego, California. Raised $2 million in a registered direct offering and concurrent private placement. SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (\u201cCalidi\u201d), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the third quarter ended September 30, 2024, and reviewed recent business highlights. \u201cCalidi continues to advance our development programs while expanding our industry-leading position in targeted antitumor virotherapies,\u201d said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. \u201cIn addition, we are pleased that Northwestern University has received U.S. FDA clearance to advance our CLD-101 program in the clinic for newly diagnosed high-grade glioma.\u201d Third Quarter 2024 and Recent Corporate Developments The U.S. Food and Drug Administration (FDA) has cleared Northwestern University\u2019s Investigational New Drug (IND) application for Calidi\u2019s NeuroNova (CLD-101). CLD-101 is a novel stem-cell based platform designed to deliver oncolytic viruses to tumors, enhancing their antitumor effects. The Phase 1b/2 clinical trial in newly diagnosed high-grade glioma is expected to commence in early 2025 at Northwestern University. Data was presented on RTNova (CLD-400), Calidi\u2019s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, at Immuno US 2024 in San Diego, California and the Society for Immunotherapy of Cancer (SITC) annual meeting. RTNova is a systemic treatment designed for reduced elimination by the humoral immune system. It targets multiple tumor sites, killing tumor cells while altering the tumor immune microenvironment. This novel systemic therapeutic approach not only facilitates easier administration but also broadens the potential patient population who can benefit from this treatment. Calidi announced in October the completion of a definitive securities purchase agreement with certain institutional investors, raising $2 million in a registered direct offering and concurrent private placement. Story Continues Third Quarter 2024 Financial Results The Company reported a net loss of $5.1 million, or $0.65 per share, for the three months ended September 30, 2024, compared to a net loss of $2.0 million, or $1.41 per share, for the same period in 2023. Research and development expenses were $2.2 million for the three months ended September 30, 2024, compared to $3.3 million for the comparable period in 2023, respectively. General and administrative expenses were $3.1 million for the three months ended September 30, 2024, compared to $4.0 million for the comparable period in 2023, respectively. The Company had approximately $1.9 million in cash and $0.2 million in restricted cash as of both September 30, 2024 and December 31, 2023. About Calidi Biotherapeutics: Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi\u2019s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi\u2019s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi\u2019s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com . Forward-Looking Statements This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company\u2019s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, and (iii) Form 10-Q filed on August 13, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time. For Investors: Dave Gentry, CEO RedChip Companies, Inc. 1-407-644-4256 CLDI@redchip.com CALIDI BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS ( In thousands except for par value data ) September 30, 2024 December 31, 2023 (Unaudited) ASSETS CURRENT ASSETS Cash $ 1,897 $ 1,949 Prepaid expenses and other current assets 324 2,354 Total current assets 2,221 4,303 NONCURRENT ASSETS Machinery and equipment, net 982 1,270 Operating lease right-of-use assets, net 3,237 4,073 Other noncurrent assets 217 373 TOTAL ASSETS $ 6,657 $ 10,019 LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT CURRENT LIABILITIES Accounts payable $ 3,574 $ 2,796 Related party accounts payable \u2014 81 Accrued expenses and other current liabilities 2,567 4,896 Related party accrued expenses and other current liabilities 496 536 Term notes payable, net of discount, including accrued interest 242 529 Related party term notes payable, net of discount, including accrued interest 2,631 278 Related party bridge loan payable, including accrued interest 217 \u2014 Related party other current liability 620 \u2014 Finance lease liability, current 69 81 Operating lease right-of-use liability, current 1,163 1,035 Total current liabilities 11,579 10,232 NONCURRENT LIABILITIES Operating lease right-of-use liability, noncurrent 2,161 3,037 Finance lease liability, noncurrent 166 216 Warrant liability 163 623 Related party warrant liability 13 48 Convertible notes payable, including accrued interest 1,773 \u2014 Related party term notes payable, net of discount, including accrued interest \u2014 2,060 Promissory note 600 \u2014 Other noncurrent liabilities \u2014 1,500 Related party other noncurrent liabilities \u2014 538 TOTAL LIABILITIES 16,455 18,254 Commitments and contingencies (Note 11) STOCKHOLDERS\u2019 DEFICIT Common stock, $0.0001 par value, 330,000 shares authorized; 9,311 and 3,552 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 1 1 Additional paid-in capital 107,408 91,383 Non-controlling interest 485 \u2014 Accumulated other comprehensive loss, net of tax (74 ) (47 ) Accumulated deficit (117,618 ) (99,572 ) Total stockholders\u2019 deficit (9,798 ) (8,235 ) TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT $ 6,657 $ 10,019 CALIDI BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) Three Months Ended September 30, 2024 2023 (Unaudited) OPERATING EXPENSES Research and development $ (2,153 ) $ (3,251 ) General and administrative (3,073 ) (3,970 ) Total operating expense (5,226 ) (7,221 ) Loss from operations (5,226 ) (7,221 ) OTHER INCOME (EXPENSES), NET Interest expense (98 ) (101 ) Interest expense \u2013 related party (134 ) (223 ) Change in fair value of debt, other liabilities, and derivatives 352 845 Change in fair value of debt, other liabilities, and derivatives \u2013 related party 28 4,473 Debt extinguishment \u2014 (139 ) Debt extinguishment \u2013 related party \u2014 (332 ) Grant income \u2014 693 Other income (expense), net 8 (8 ) Total other income (expenses), net 156 5,208 LOSS BEFORE INCOME TAXES (5,070 ) (2,013 ) Income tax credit (provision) 1 (11 ) NET LOSS $ (5,069 ) $ (2,024 ) Net loss attributable to noncontrolling interest (15 ) \u2014 NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST $ (5,054 ) $ (2,024 ) Deemed dividend on warrants \u2014 \u2014 NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (5,054 ) $ (2,024 ) Net loss per share; basic and diluted $ (0.65 ) $ (1.41 ) Weighted average common shares outstanding; basic and diluted 7,824 1,431 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CLDI", "date": "2024-11-12T22:29:00+00:00", "sentiment": {"score": 0.7813567575067282, "confidence": 0.7900689840316772, "probabilities": {"positive": 0.7900689840316772, "negative": 0.008712226524949074, "neutral": 0.20121872425079346}}, "embedding": [-0.1255771964788437, -0.1229533702135086, -0.10395549237728119, -0.20732443034648895, -0.015162462368607521, -0.1946438103914261, -0.1635139435529709, 0.036978669464588165, 0.18191897869110107, 0.13217899203300476, -0.025674551725387573, -0.003951298072934151, 0.03883517533540726, 0.05667908862233162, -0.09257085621356964, 0.027902670204639435, 0.06422916054725647, 0.023377126082777977, -0.041135989129543304, 0.1091773584485054, -0.054950207471847534, 0.057687558233737946, 0.10963530838489532, 0.07982885837554932, -0.07994261384010315, 0.040575262159109116, -0.12113398313522339, -0.059357836842536926, -0.23844125866889954, 0.043919049203395844, 0.03491415083408356, 0.04939277842640877, -0.11074528098106384, -0.010060625150799751, 0.018062038347125053, -0.06489971280097961, -0.22274571657180786, 0.031941503286361694, -0.23834705352783203, 0.00442623533308506, -0.09135795384645462, -0.08403909206390381, -0.04636994004249573, 0.13906291127204895, -0.01652078703045845, -0.24178197979927063, -0.17007575929164886, -0.08241970837116241, 0.08111746609210968, 0.14600203931331635, -0.08893819153308868, 0.004045475274324417, -0.05743228644132614, 0.13603302836418152, -0.07147947698831558, 0.06380432844161987, -0.10392741113901138, 0.05284005030989647, -0.03131328523159027, 0.20706889033317566, 0.03657017648220062, -0.0751725360751152, -0.014257729053497314, 0.015609526075422764, 0.1137654036283493, -0.024813443422317505, -0.08232329040765762, 0.0069402651861310005, -0.06274505704641342, -0.06689469516277313, 0.1627112329006195, -0.05240441486239433, 0.014370199292898178, 0.11628514528274536, -0.008986284956336021, 0.06802468001842499, 0.23941510915756226, 0.21447020769119263, 0.2204456925392151, -0.17099860310554504, 0.12226955592632294, 0.052466198801994324, 0.11349205672740936, 0.029299143701791763, 0.07157810777425766, 0.07838037610054016, 0.10019974410533905, 0.2972891628742218, 0.04904744774103165, 0.13573695719242096, 0.22453489899635315, 0.04973611235618591, 0.006525176577270031, 0.0836489349603653, -0.14141465723514557, -0.008880817331373692, -0.06292179971933365, -0.07838776707649231, 0.018136894330382347, -0.09737629443407059, -0.10125494003295898, 0.016488421708345413, -0.07215982675552368, -0.17398250102996826, -0.019331347197294235, -0.01767936535179615, 0.04061105102300644, 0.01807304657995701, -0.07505623996257782, 0.002859479747712612, 0.03657214343547821, 0.07040729373693466, 0.03979337215423584, 0.09560613334178925, 0.02408246137201786, 0.2896699905395508, -0.05296526476740837, 0.06598668545484543, 0.20315715670585632, -0.05195730924606323, -0.028983989730477333, -0.024462196975946426, -0.10064157098531723, -0.19652193784713745, 0.04978320375084877, 0.06945636868476868, -0.19930419325828552, 1.194311370516663e-32, 0.033388447016477585, 0.04740268737077713, -0.0811832994222641, 0.014357447624206543, -0.12841364741325378, -0.05856472998857498, 0.05658908188343048, 0.09305807948112488, -0.22654448449611664, -0.12551364302635193, -0.05611499398946762, 0.07445374876260757, -0.0412764735519886, 0.19671663641929626, -0.07938728481531143, -0.11275429278612137, -0.005870499648153782, -0.0054367296397686005, -0.018239783123135567, -0.09872405230998993, 0.08012571930885315, 0.07185464352369308, -0.034070197492837906, 0.011145454831421375, -0.13194014132022858, 0.12089516222476959, -0.273723304271698, 0.1235005259513855, 0.1469864398241043, 0.07528940588235855, -0.09329212456941605, 0.0003502778708934784, 0.01884339563548565, -0.0941857323050499, -0.02425386756658554, 0.019856799393892288, -0.016522474586963654, -0.09795545041561127, -0.06026214361190796, 0.2142610251903534, 0.03439021855592728, 0.13497677445411682, -0.06796915829181671, -0.08791908621788025, 0.07550978660583496, -0.07562486827373505, -0.025598522275686264, 0.145270437002182, 0.05222322419285774, 0.02143314853310585, -0.0899430513381958, -0.0035754088312387466, 0.00698210671544075, 0.003753670724108815, -0.06283622980117798, 0.03228241205215454, -0.09648548066616058, -0.10967381298542023, 0.04501187056303024, -0.005948507692664862, 0.02219255082309246, 0.1041373759508133, -0.10414671897888184, 0.06592480093240738, -0.08723173290491104, -0.05733514577150345, -0.018295684829354286, -0.1370585858821869, -0.05058731138706207, 0.10201486945152283, 0.0036803577095270157, -0.008243258111178875, 0.18990382552146912, 0.027794618159532547, 0.1870618462562561, -0.08480795472860336, 0.10544084012508392, 0.03550373762845993, -0.012744060717523098, 0.0743492916226387, 0.03973376378417015, 0.06325995177030563, -0.0980403795838356, 0.09906545281410217, 0.04456762969493866, 0.010113762691617012, -0.0442298986017704, 0.06748507171869278, -0.1373334527015686, -0.06276333332061768, 0.1108960434794426, -0.06893042474985123, 0.0942438468337059, 0.06968558579683304, -0.06826988607645035, -1.0610826775043881e-32, 0.027586331591010094, -0.043832927942276, 0.04911498725414276, -0.05548530071973801, 0.003113160841166973, 0.21131369471549988, 0.04489587992429733, -0.2047615945339203, 0.05453776568174362, -0.15308761596679688, 0.005591701716184616, 0.09115033596754074, 0.07880818843841553, -0.08359846472740173, -0.020606432110071182, -0.026250183582305908, -0.09275174885988235, -0.165643572807312, -0.10069790482521057, -0.05768478289246559, 0.008943958207964897, 0.2802239954471588, -0.05297603830695152, 0.04234734922647476, 0.05717899277806282, -0.11046753823757172, 0.1451888382434845, 0.051003746688365936, 0.05212674289941788, -0.009914593771100044, -0.07041612267494202, 0.009847953915596008, -0.3090139627456665, 0.09460003674030304, -0.014622886665165424, 0.027372239157557487, 0.18027298152446747, -0.2212005853652954, -0.03848104551434517, -0.06621110439300537, 0.009371410124003887, -0.053654350340366364, -0.21377193927764893, -0.033208031207323074, 0.06135338172316551, 0.04091128706932068, 0.07206232100725174, 0.13220584392547607, 0.07887870073318481, 0.11641912162303925, -0.04715079069137573, 0.01751493290066719, -0.006399700418114662, -0.022923581302165985, -0.00995359942317009, 0.038322340697050095, -0.029406432062387466, 0.017949439585208893, -0.0896570086479187, 0.022283144295215607, -0.03384818136692047, 0.05282868444919586, -0.01023232564330101, 0.010671356692910194, 0.14951656758785248, 0.25558239221572876, 0.15268062055110931, 0.11978153139352798, -0.04546993225812912, -0.13024814426898956, -0.03797439485788345, -0.05087616667151451, -0.018295133486390114, -0.1656929850578308, 0.00021402398124337196, 0.09632842242717743, -0.007598224561661482, -0.1456545740365982, -0.053707946091890335, 0.07708695530891418, 0.06204070895910263, -0.013516277074813843, 0.015311084687709808, 0.028073590248823166, 0.11648000776767731, 0.15236982703208923, -0.0022192923352122307, -0.03448740765452385, -0.04104479402303696, 0.05097176134586334, -0.060914576053619385, -0.15518280863761902, -0.003825034014880657, 0.10521821677684784, 0.0357624851167202, -1.0021472007792909e-07, 0.183259516954422, -0.04778203368186951, -0.06862209737300873, -0.09844458103179932, 0.05363873392343521, -0.08110448718070984, 0.0019092494621872902, 0.10880551487207413, 0.0036247295793145895, 0.16552332043647766, 0.03879460319876671, 0.1576290726661682, -0.18717199563980103, 0.05514764040708542, -0.049922555685043335, 0.19133102893829346, 0.03148394450545311, 0.03899169713258743, -0.07072803378105164, -0.061840932816267014, -0.0652337595820427, 0.020483605563640594, -0.01567913591861725, -0.031752072274684906, -0.05697516351938248, -0.09682022780179977, -0.007525180466473103, 0.02113817259669304, 0.05764096975326538, -0.14024004340171814, -0.05730336159467697, -0.08315987884998322, 0.03790261968970299, -0.061899326741695404, 0.02053423412144184, -0.08649253845214844, 0.03571326285600662, 0.037868596613407135, 0.1564437747001648, 0.2343912422657013, 0.12561586499214172, -0.027128830552101135, -0.0774640291929245, 0.015780219808220863, -0.0053812796249985695, 0.016090551391243935, -0.1860056072473526, -0.05948974937200546, -0.011371365748345852, -0.07689669728279114, -0.023671947419643402, 0.01571292243897915, -0.05000089108943939, -0.09739305078983307, -0.114632748067379, 0.25128573179244995, -0.0639398992061615, -0.10607533156871796, -0.02693134732544422, -0.04189733415842056, 0.04660577327013016, -0.0991005152463913, 0.11196418106555939, 0.02781914547085762], "changes": {"1wk": 13.74408600425244, "1mo": -11.3744029506956}}]